{{ site.specific_data.Twitter }}
Inside Kennedy's FDA: A Lawless, Reckless Rush To Approve Untested Peptides

Inside Kennedy's FDA: A Lawless, Reckless Rush To Approve Untested Peptides

In years past, journalists covering any Food and Drug Administration advisory committee meeting would invariably add this boilerplate sentence to their stories: “The FDA almost always follows the advice of its advisory committees.”

That axiom will be put to the test after the agency’s Pharmacy Compounding Advisory Committee yesterday approved four untested peptides for manufacturing and sale. The 12-member committee, half of whom will financially benefit from the recommendation, will consider another three today.

None meet the FDA’s standards for safety and efficacy. Indeed, according to the FDA’s professional staff who reviewed the medical evidence behind the drugs, none have even been tested for either of the two requirements that have been the twin touchstones for agency drug approvals since 1962.

The committee contains eight new members handpicked by Robert F. Kennedy Jr.’s Health and Human Services Department. None have been vetted for conflicts of interest by FDA staff, who traditionally perform that task. Six of the eight have crude conflicts in that they run wellness, longevity, and regenerative medicine clinics that prescribe peptides.

The roster also includes Robert Harshbarger, a Republican state senator from Tennessee. His mother, Rep. Diana Harshbarger (R-TN), is a pharmacist who last year introduced legislation that would, among other things, “remov(e) outdated labeling restrictions” on manufacturing facilities that mass produce peptides.

An entire industry has grown up around the manufacture and sale of peptides, small protein building blocks that allegedly perform miracles like wound healing, muscle building, and promoting longer life. They’ve become mainstay treatments at medical clinics and spas across the country where people with money to burn (no insurance will cover them) go for treatment, and are easily available through telehealth firms where medical professionals (perhaps licensed, perhaps not, who knows?) “prescribe” them for “patients” they’ve never seen, who self-describe their symptoms over the phone or online.

Peptides are being promoted by online influencers like Joe Rogan. They have a champion sitting atop the Health & Human Services Department. And they have received kind words from the paragon of ill-health (physical as well as mental) sitting in the White House. For more background on peptides, see this article on GoozNews published three months ago.

Today, let me address one simple fact. The FDA is not required to follow the advice of this illegally constituted advisory committee.

Why illegally constituted? The Federal Advisory Committee Act (FACA), signed into law by President Richard Nixon in 1972, prohibits any scientist, official, consumer or patient representative from sitting on a federal advisory committee if they have a financial stake in the outcome of its deliberations.

The sole exception is if their expertise is crucial to carrying out the committee’s charge and cannot be obtained elsewhere. In that case, the agency constituting the committee may issue a waiver outlining why their expertise is necessary. The agency issuing those waivers must post them on the government website that lists the committee rosters (there are hundreds across the federal government).

Where are the waivers?

The General Services Administration website that hosts the searchable FACA database is currently non-operational. In 2018, the first Trump administration outsourced management of the database to Salesforce, the software giant based in San Francisco that manages sales for corporations. Instead of maintaining a searchable database, Salesforce began posting Excel files with the data. The company has not updated the files on the GSA website since 2024, that is, since the start of the second Trump administration.

Some enterprising journalist might consider making a Freedom of Information Act request to GSA and HHS for a copy of the waivers issued when this new committee was created.

Yesterday’s recommendations, and three more certain to follow today, will present a major challenge for acting FDA commissioner Kyle Diamantas. Prior to Trump’s appointment to run the food division at the agency in 2025, the 38-year-old lawyer worked at the legal giant Jones Day representing food, beverage and tobacco industry clients. It is highly unusual for a non-physician or scientist to run one of its key divisions, much less the entire FDA.

Yet, when Diamantas was chosen in May to replace Marty Makary, he received high praise in the trade press that covers the FDA for his one-year tenure at the food division, whose staff had been decimated by DOGE. Its previous director issued an angry resignation letter after the mass layoffs.

Here’s what Stat reporter Lizzy Lawrence had to say:

Leaders in the food industry, public health groups, and FDA career staffers have found that Diamantas exceeded expectations. As Diamantas takes the reins at the FDA, STAT spoke with more than 10 of these stakeholders, as well as former FDA commissioners and Diamantas’ former colleagues. They all described him as thoughtful and serious, someone who does his homework before meetings and listens to the experts in the room. Crucially, Diamantas has earned the trust of key career staff.

The career staff did its best yesterday to lay the facts before the stacked committee. The seven peptides under consideration for being legalized for production by compounding pharmacies have never been tested for medical efficacy in human beings. Virtually all of the safety testing has been done in animals, not humans.

In other words, the physicians or other medical personnel offering these alleged medications are not engaged in the off-label prescribing, which is allowed. There are no labels.

The long briefing monographs prepared for the committee for each of the seven peptides couldn’t have been more clear. The summary statements near the top stated in each case:

We have evaluated publicly available data on the physicochemical characteristics, historical use, safety, and effectiveness in compounding of these substances. For the reasons discussed below, we believe the evaluation criteria weigh against placing (name of peptide) on the list of bulk drug substances that can be used to compound drug products.

Attorney Diamantas. The ball’s in your court.

Blaming Canada For Wildfire Pollution? Republicans Should Look In The Mirror

Blaming Canada For Wildfire Pollution? Republicans Should Look In The Mirror

The Swiss air quality company IQAir called Chicago, the city where I live, the most polluted in the world. Judging from the haze outside my home office window this morning, not much has changed.

The Chicago Tribune reported that PM2.5 pollution (the most dangerous since small particulate matter from wildfires, internal combustion vehicles and industrial pollution easily enters the lungs and bloodstream) tripled the city’s previous high, which was already deemed hazardous to health. Some northern suburbs saw their previous highs quintupled.

Those previous recorded highs were set during the 2023 Canadian wildfire season, the worst until this year. Summer has been cancelled, one headline said, as public health officials warned everyone in the upper Midwest, Northeast and mid-Atlantic states to remain indoors.

Cancelling summer is depressing. Cancelling life is more important.

As of yet, there has been very little reporting about the immediate health effects of the hazardous conditions suffocating central Canada and the north and northeastern third of the U.S. Studies of previous PM2.5 wildfire seasons estimated at least hundreds and probably thousands of people died prematurely from acute asthma and cardiovascular attacks. Longer term, the studies projected thousands more will die prematurely from increased cases of lung and other cancers, heart attacks, and strokes.

On July 17, the Associated Press reported some of the research behind those estimates. To quote from its story:

On average 24,100 people died each year in the Lower 48 states between 2006 and 2020 due to long-term exposure to tiny particles from wildfire smoke, according to a study this year in the journal Science Advances. A Stanford study projects that U.S. wildfire smoke deaths will increase with climate change and by midcentury hit an annual cost of $244 billion in terms of the economic value the government puts on each life.
On a global scale, wildfire smoke particles cause 677,745 deaths annually, with almost 39% of them children under age 5, according to a 2021 study that combined observations, studies on how the body responds to the particles and computer models to calculate the toll.

That AP story arrived just as I was concluding my own brief review of the medical literature. Here are just a few of the studies I found:

  • A Canadian study in Geohealth of the health effects in Canada from wildfires between 2019 through 2023 found immediate deaths increased anywhere from 49 to 400 per year. Increased deaths from chronic exposure ranged anywhere from 660 to 5,400 deaths per year. Canada’s population is one-eighth that of the U.S.
  • A U.S.-led study in Environmental Science & Technology Letters of the effects from the 2023 Canadian blazes found a three-fold increase in attributable deaths from smoke exposure.
  • An Australian study in the American Journal of Obstetrics & Gynecology found asthmatic mothers-to-be exposed to at least 10 days of wildfire smoke in the first five months of pregnancy (compared to those with less or no exposure) resulted in four times more low birthweight babies, three times more pre-term babies, and five times more babies requiring neonatal intensive care.

Each of those studies was published earlier this year.

Who deserves the blame?

How has the majority party in Washington responded to this unprecedented outbreak of forest fires in our northern neighbor? They’re blaming Canada for an alleged lack of response.

Sen. Bernie Moreno (R-OH) announced last week that he plans to introduce the CANADA FIRE act (Countering Atmospheric Nuisances Arising from Drifting Airborne Foreign Incendiary Residual Emissions Act”). “My bill will declare an emergency, sanction all Canadian officials responsible, and study a victims compensation fund driven by imposing additional tariffs,” he said in a prepared statement.

Blaming political opponents for the increasing devastation from wildfires has become the go-to Republican trope for deflecting attention from the overwhelming consensus that greenhouse gas emission-driven global warming is entirely responsible for the unsurprising escalation in forest fire ferocity. President Trump took the lead last year when he accused California Gov. Gavin Newsom’s environmental and water management policies for the Palisades and Eaton wildfires, which led to 41 immediate deaths, another 440 health-related deaths, destroyed over 18,000 structures and forced over 200,000 from their homes.

Those charges were immediately debunked on the PolitiFact website. “Regional water reservoirs in Southern California are at historical highs,” the Poynter Institute’s factchecking organization noted. “Hydrants ran dry during recent firefighting because the city’s water infrastructure was not built to respond to fires so large.”

The real culprit

The Atlantic magazine environmental reporter Joshua Partlow offers a brief summary of why this year’s Canadian forest fires are shaping up as the worst ever.

When the boreal forests of Canada catch on fire, no one can do anything about it in many cases. The forests are part of Earth’s largest land biome, a greenbelt of wilderness that encircles the globe, and they’ve been suffering from the planet’s thermostat being jacked up. Wood-boring pests that flourish in milder climates have swept north and east, through tens of millions of acres. Droughts and dwindling snowpack have stressed the trees. They are ready to burn.

Trees are not just innocent victims of global warming. They are our most important allies in the fight against it. Why? Because trees take in carbon dioxide and through the miracle of photosynthesis pump out oxygen.

The majority of the earth’s arboreal forests lie in the upper reaches of the northern hemisphere. That fact is aptly reflected in the following chart. The downward-sloping portions of the saw-toothed line reflects the decline in atmospheric CO2 concentrations during the northern hemisphere’s spring and summer months.

Bottom line: Climate change’s impact on Canada and Russia matters a lot.

The vast forested lands of those two countries are the largest component of the planet’s lifeline. They are being assaulted daily by the warming temperatures caused by fossil fuel emissions. When they burn, it’s like puncturing a hole in our life preserver.

And who deserves the most blame for those fires when we look around the world? It is the current U.S. government and its environmental policies — not malfeasance by the Canadian government for failing to contain the growing number of forest fires in its 1.4 million square miles of forest land, which is more than twice the size of Alaska and constitutes nine percent of the world’s total.

Let us now review current U.S. policy as pertains to global warming:

  • The current president calls global warming a hoax.
  • His government supports more coal-fired plants and less renewables like wind and solar to produce electricity.
  • His Supreme Court majority in 2022 severely limited the government’s ability to regulate CO2.
  • His Environmental Protection Agency initiated at least 70 actions to roll back rules designed to protect the environment and limit global warming.
  • He withdrew the U.S. from the Paris Agreement on fighting global warming.
  • His science agencies de-funded research into the causes and effects of global warming.
  • His Interior Department has opened federal lands, including national treasures like the Arctic Wildlife Preserve, to fossil fuel exploration.
  • His State Department has destroyed the Agency for International Development, which provided crucial assistance for less developed countries that wanted to combat their own contributions to global warming.

If Americans want to become part of the fight against the health harms of global warming, the place to start is in Washington, not Ottawa.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

Trump's Scientific Quackery Provokes Fresh Opposition (You Can Push Back Too)

Trump's Scientific Quackery Provokes Fresh Opposition (You Can Push Back Too)

Just a short note this morning to highlight the outpouring of opposition to the Trump regime’s attempt to impose its political priorities on federally-funded scientific research, which I called modern-day Lysenkoism in this GoozNews article in early June when the rule was first proposed.

Who was Trofim Lysenko? He was the political hack Josef Stalin put in charge of Soviet science in the 1930s because the dictator agreed with his theory rejecting Mendelian genetics in favor of his pet theory that learned behaviors could be inherited. Russia’s contributions to medical and biological science never recovered.

An Office of Management and Budget rule proposed in late May would require all federal grants (including the National Institutes of Health, the National Science Foundation, and virtually every agency of the federal government) gain approval from political appointees at the granting agency. The regime’s attempt to impose political control by executive order was rejected by the courts for failing to follow the federal law that requires rulemaking with public comment to make such a change.

An administration spokesperson gave Axios this boilerplate explanation for the proposal: "Federal grants were politicized under the last administration to promote a far-left DEI (diversity, equity and inclusion) agenda.… That ends now."

The unspoken agenda is the Trump regime’s desire -- epitomized by Health An Human Services Secretary Robert F. Kennedy Jr. -- to fund pseudo-scientists who back quack theories opposing vaccines and water fluoridation, and support scientists who claim efficacy for drugs and devices never subjected to clinical trials.

Significantly, Big Pharma has finally weighed in on the gutting of science that is the basis for their entire industry (something it has so far failed to do regarding the regime’s undermining of the Food and Drug Administration, which regulates its products). The proposed changes to research funding decisions could introduce a level of unpredictability that would weaken the scientific ecosystem,” a spokesperson for PhRMA, the industry trade group, told Axios.

“At a time of intense global competition, creating uncertainty in research funding risks driving talent, discoveries and investment to other countries, ultimately slowing the development of lifesaving treatments for American patients and ceding U.S. leadership.”

The comment period remains open until next Monday, July 13. You can weigh in by clicking here: https://www.federalregister.gov/documents/2026/05/29/2026-10817/regulation-for-federal-financial-assistance.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

Erupting Crisis Of Uninsurance, Created By Republicans, Will Soon Engulf US Families

Erupting Crisis Of Uninsurance, Created By Republicans, Will Soon Engulf US Families

The GOP-fostered uninsurance crisis is growing faster than a newborn volcano, one that will do grave harm to those directly affected and later this year will begin spewing its molten crap on everyone.

The Associated Press reported Friday that nearly 3 million people dropped Obamacare health insurance plans during the first two months of 2026. That’s a 13 percent fall from the 22.1 million people who purchased individual or family plans on the exchanges in 2025.

That’s already 40 percent of the total the Congressional Budget Office projected would drop coverage for the entire year because the GOP-run Congress refused to reauthorize those Biden-era subsidies during last year’s budget negotiations. That left millions of low-wage workers whose employers don’t provide coverage with out-of-pocket premiums they can no longer afford without the extra help.

The end to people dropping coverage is nowhere in sight. The CBO conservatively estimated 7.5 million people would drop Obamacare coverage this year. If the first quarter average holds for the rest of the year, that number will soar to more than 10 million.

Add to that the millions of people being thrown off Medicaid due to the new work requirements and bureaucratic hurdles thrown in their way, the ranks of the uninsured will likely see its largest increase in years when data for 2026 is released next year. Last May, the CDC reported 28 million people or 8.3 percent of the population did not have health insurance in 2025. With the Trump regime adding another 10 million people or more to the ranks of the uninsured, the uninsured rate is likely to jump to more than 11 percent.

(That’s my calculation: Put 38 million uninsured over a population projected to grow to 344 million this year and you get an 11 percent uninsured rate.)

How about the rest of us?

What will that mean for the 156 million or so people with employer-based coverage? Their rates will be jacked up by insurance companies to pay for the uncompensated care hospitals deliver to the uninsured in nation’s emergency rooms, where, when they get sick, they turn for care since ERs legally cannot turn them away. Moreover, they will likely be far more costly to care for since ERs are the most expensive place to get care, and they will have waited until their conditions had worsened to the point where they had to seek care.

We’re already beginning to see evidence of the premium price spikes to come. Nona Tepper of Modern Healthcare reported last week that health insurers’ preliminary filings with state regulators for individual plans sold on the exchanges will show big premiums increases next year. Employer surveys showing next year’s premiums usually aren’t released until the late fall.

Leaving people uninsured is about the stupidest and most inhumane policy any society could adopt, especially one that can afford to ensure than everyone has coverage. But, as Forrest Gump liked to say, stupid is as stupid does.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News


Health Insurance Premiums Are Set To Soar Just Before Midterm Elections

Health Insurance Premiums Are Set To Soar Just Before Midterm Elections

Anyone whose employer provides health coverage knows the drill. Each fall, they are offered a menu of potential health care plan choices for the following year.

It usually includes three options. First, there is a preferred provider plan, which pays most of the bills, has few limits on provider choice, and has the highest paycheck deduction. Second comes a mid-priced health maintenance organization plan, where provider networks are limited, prior authorization rules are strict, and co-pays and deductibles are moderate. Finally, there is a high-deductible plan, which has the smallest paycheck deduction, but can leave an individual or family with large, unaffordable bills when anyone covered by the plan requires hospitalization or expensive treatment.

The employer share for any one of those plans (the average family plan cost is nearing $30,000 a year) usually hovers around 75 percent of the total cost. Workers pick up the other 25 percent through a payroll deduction. In the decade after passage of the Affordable Care Act, the annual increase averaged around 6-7 percent or about the same rate as economic growth after inflation was taken into account.

But during the pandemic, health care cost began a rapid ascent to around 8-8.5 percent annually. Now, it has taken another upward lurch.

A new survey of health care actuaries by PwC (formerly known as Price Waterhouse Coopers) found private health insurers medical claims costs are rising at a nine percent clip this year and are expected to rise by a similar rate next year. Last year’s survey pegged this year’s expected cost increase at 8.5 percent.

“Health plans are projecting the highest medical cost trend in nearly two decades,” the consulting group said in its analysis. “Payers and employers face mounting pressure to act.”

This could prove a financial fiasco for people on employer-based plans, which cover about 160 million workers and their families. They will likely face co-premiums, co-pays and deductibles in their 2027 plans that are rising at nearly three times the rate of inflation.

And it could be a lot worse than that. As actuaries inside the insurance companies map out their costs, they will have to take into account the additional price increases levied by hospital systems due to rising utilization, AI-enabled billing tactics, and what’s likely to be a rapid rise in unpaid bills.

The sharp cutbacks in Medicaid contained in the One Big Ugly Bill signed by President Trump last year will hit in full force in 2027. Well over ten million impoverished Americans are expected to lose coverage due to their inability to leap over the bureaucratic hurdles erected to enforce the legislation’s work requirements.

Millions more are dropping coverage and falling into the ranks of the uninsured due to the Republicans’ refusal to extend the expanded subsidies in ACA plans enacted by Democrats during the Biden administration. Both cuts will trigger a huge increase in uncompensated care at the nation’s safety net hospitals that serve low- and moderate-income communities.

Like all hospitals, safety net hospitals must provide emergency treatment for anyone who lands on their doorstep thanks to the 1986 Emergency Medical Treatment and Labor Act, which was signed into law by President Ronald Reagan. Unlike their suburban counterparts, who face far fewer cuts because they serve mostly the privately insured, these safety nets have fewer resources and small or no endowments to fall back on.

The final rates will be determined by medical actuaries inside the insurance firms over the next few months. The rates for 2027 are usually unveiled in mid-October.

How will employees respond if they see their paycheck premiums rising at a near double-digit rate? Many more low-income workers will opt into high-deductibles plans, which will leave many with unpayable medical debt because they can’t afford the out-of-pocket expenses when someone in the family gets sick. More middle-class workers will opt into HMOs with their network limitations and prior authorization restrictions to save on their upfront costs.

The nation’s employees with employer-sponsored coverage will be making those decisions starting on November 1, the traditional date for open enrollment for the ensuing year. That’s two days before the midterm elections.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News


Health Inflation Won't Stabilize Until Politicians Confront Monopoly Hospitals

Health Inflation Won't Stabilize Until Politicians Confront Monopoly Hospitals

Today’s inflation report is a wake-up call for wannabe-be health care reformers. It provides the perfect opening for injecting how to control hospital prices into this year’s political debate.

The overall inflation rate ratcheted up 4.2% last month, driven largely by fast-rising gasoline and diesel prices that are entirely due to Trump’s ill-conceived, undeclared and unwinnable war against Iran. If you take out food and energy, inflation was up “only” 2.9%. That’s still nearly a full percentage point above the Federal Reserve Board’s target level.

But dig a little deeper into the numbers and you find medical inflation, which many Americans consider their most pressing concern, rose 3.6% over a year ago, faster than the core inflation rate. Prices for hospital services were almost entirely responsible for the jump — up 5.7% year over year.

The second largest component of health care services — physician fees — grew at a much slower pace, up 2.8% or about the same rate as core inflation. Drug prices fell 2.1% over the past year.

The drug price component of the consumer price index is somewhat misleading since the Bureau of Labor Statistics measures the change in existing drugs and generics, not the price of new drugs coming to market. Big Pharma introductory prices for new drugs like the popular GLP-1s have reached sky-high levels, which often come down somewhat after launch to attract more customers.

Novo Nordisk’s Wegovy, for instance, came to market at $1,349 a month, but now can be purchased for as little as $350 a month. That shows up as a major price decline in the index, even though many consumers still can’t afford it because their insurance companies won’t pay for it.

Speaking of insurance companies, the New York Times reports their prices fell 6.4% over the past year, which is hard to understand given the rising prices for almost all of the services they finance with the premiums collected from employers and consumers. I also don’t know where the Times got that data since I couldn’t find it in either the Bureau of Labor Statistics press release or the agency’s detailed data tables.

I suspect at least some of the decline in health insurance prices reflects what individuals pay for plans sold on the exchanges, where millions of people are switching to bronze plans from pricier silver plans to lower their upfront premiums. Unfortunately, when they use their insurance, they will have much higher out-of-pocket costs.

This isn’t a price decline. It’s a cost-shift. I suspect some health care economists will insist cost-shifting doesn’t exist, claiming it reflects consumer preference for the cheaper item.

None of this is good news for the nation’s hospital leaders, who have launched a major media campaign to shift the blame for rising health care prices onto health care’s other special interests. The American Hospital Association’s March report “The Cost of Care” blamed the surging cost of drugs, labor and supplies for their price increases.

Some of that is true, but the document offers a classic inside-the-beltway manipulation of data to make its case. The AHA report used a consulting firm’s data to show that “advertised salaries for registered nurses have grown 26.6% faster than the rate of inflation over the past four years. These increases are essential to maintain staffing levels but also contribute to the overall financial challenges hospitals face.”

Let’s take a closer look at that claim. The cumulative inflation rate between May 2022 and May 2026 was 13.8%, an average of about 3% a year before compounding. A 26.6% increase brings that to 17.5% over four years, or an average of about 4% before compounding. If anything, the AHAs data shows nurse wages have gone up about a percentage point faster each year than underlying inflation, which is what you might expect from a sector of the economy with a large union membership. Hospital prices, on the other hand, have gone up about two to three percentage points faster than inflation.

Higher wages for nurses can actually be a good thing for hospitals, which frequently hire traveling nurses to staff unexpected surges in patient load or temporarily fill open positions. The staffing firms that provide those nurses (like publicly-traded AMN Healthcare) impose huge mark-ups on the underlying nurse salaries, which make their cost considerably higher than hiring permanent staff. The same is true for many of the support staff occupations inside hospitals. If hospitals paid adequate wages and provided decent working conditions for their permanent staff, perhaps they wouldn’t have to rely on high-priced staffing firms to keep their facilities running.

Meanwhile, the House Energy and Commerce Committee today held a hearing on Capitol Hill to promote greater hospital and insurance company price transparency, an issue for which there is bipartisan support. The assumption is that greater transparency will promote competition and allow health care “consumers” to shop.

This ignores the economic realities of health care. First, only a small portion of health care services are shoppable. Second, there is little or no competition in most markets. Third, even where competition exists, most patients are locked into networks and hospital systems that offer a closed loop of primary care and specialty physician providers. More than half of all doctors in the country now work for either hospitals or insurance companies.

“The monopolization with regard to hospitals and so many health care interests exists and is getting worse,” Rep. Frank Pallone Jr. (D-NJ), the ranking member of the committee, said in his opening statement. “So, let’s not forget that … to use transparency more effectively …, we have to also look at the competitive environment to make sure it truly is competitive.”

I’m not holding my breath for Republicans to endorse greater antitrust enforcement. But it is disappointing that Democratic leaders are putting all their marbles on competition policy to bring down hospital prices, which under the best of circumstances will take years of court battles to bring results.

I didn’t get a chance to listen to the hearing today, but I bet not a word was said about putting hospitals on budgets, putting physicians on salaries and giving administrators the freedom to deploy their financial resources in ways that deliver better health outcomes. The American people are ready for meaningful change. So far, such proposals are missing from this year’s health care debate as we head into the mid-term election season.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

Bullying Trump Officials Wage Stalin-Style War On Science In Washington

Bullying Trump Officials Wage Stalin-Style War On Science In Washington

A little over a year ago, the Trump-appointed interim U.S. Attorney for the District of Columbia sent threatening letters to editors of several leading medical journals, including the New England Journal of Medicine, Obstetrics and Gynecology, CHEST, and the American Journal of Public Health. Edward R. Martin, the conservative activist-attorney who now manages pardons for the president, questioned their editors’ alleged bias against “competing viewpoints” when deciding what to publish.

Several replied with ringing defenses of their editorial practices. “As practicing physicians, our editors recognize our responsibility to doctors and patients. We use rigorous peer review and editorial processes to ensure the objectivity and reliability of the research we publish,” NEJM editor Eric Rubin wrote Martin. “We support the editorial independence of medical journals and their First Amendment rights to free expression.”

Critics warned the letters true intent was “to send a message to academic publishers to avoid crossing the Trump administration and push them to publish viewpoints more favorable to the current administration,” STAT reported at the time.

The Health and Human Services Department under Robert F. Kennedy Jr. subsequently canceled much of the research into racial health disparities, reproductive health and the social determinants of health, branding such studies as “woke” and a waste of taxpayer money. A Trump administration HHS spokeswoman said, “Spending billions on divisive, politically driven D.E.I. (diversity, equity and inclusion) initiatives that don’t deliver results is not just bad health policy — it’s bad government.”

Kennedy sent clear signals prior to his confirmation that he intended to attack science. During his run for president, he threatened to prosecute medical journals under federal anti-corruption statutes for allowing drug companies to influence their editorial decisions. His anti-vax organization’s research, which claimed vaccines caused autism, never made it past journal editors and peer reviewers. The one study published over a quarter century ago that found such a link had been retracted as fraudulent.

“There is a substantial resentment that they’ve not been able to get traction for these heterodox ideas within the scientific community itself,” Carl Bergstrom, an evolutionary biologist at the University of Washington and a frequent critic of low-quality science, told Stat. “So, they are willing to tear down the fabric of science in order to try to impose these ideas on the community.”

Kennedy’s group wasn’t the only Trump coalition faction seeking to force changes in the scientific publication process. Christian conservatives have frequently attacked the American College of Obstetricians and Gynecologists (ACOG) and their publications for promoting abortion, LGBTQ rights, and birth control access.

Just two weeks before the interim district attorney letter was sent to Obstetrics and Gynecology (ACOG’s flagship journal), the Alliance Defending Freedom, a Christian conservative advocacy law firm, demanded the HHS secretary cut funding and investigate the group. “Paying ACOG to spend taxpayer dollars (is) inconsistent with this administration’s policies on the biological basis for sex, ending racial discrimination and ‘equity’ programs, and preventing taxpayer funding for the promotion of abortion,” its letter said.

A new assault on science

This week the Trump regime escalated its war on science by attacking the independence of the vetting process for studies appearing in medical and scientific journals. For the most part, the process relies on independent peer review, both at the agency level when making grants and at the journals after study results are submitted for publication.

The Office of Management and Budget proposed a rule that will subject every federal research grant to a second political review. The rule, which is open for public comment until July 13, essentially gives political appointees at agencies like the National Institutes of Health, the National Science Foundation and the National Oceanographic and Atmospheric Administration veto power over grant proposals.

The proposed rule also allows political appointees to summarily cancel already-awarded grants; use what an editorial on the Science magazine website called “vague criteria” for giving favored institutions preferable treatment; and subject every grant that involves spending money abroad to political review. “This bureaucratic hurdle would effectively prevent most if not all (international) partnerships from moving forward,” an editorial in Science said.

Even before releasing this proposed rule, the regime’s editorial intimidation strategy, and the publicity surrounding the initial letters sent to journal editors, triggered a dramatic slowdown in publication of articles on the subjects that Trump’s most avid supporters find objectionable. This week, I conducted a small research project measuring the number of articles catalogued on the National Library of Medicine’s PubMed website that mention various hot-button issues in either their title or abstract.

Here’s what I found: Over the first five months of 2026, when compared to the similar period a year ago, there was a 24 percent drop in articles and research studies published about abortion and LBGTQ health; a 23 percent reduction in articles published in the medical literature that include the terms “race” or “racial” and “health disparities”; and a 15 percent decline in articles mentioning the “social determinants of health” and “health disparities.”

The reductions in published research in those four areas far exceeded the general slowdown in published new studies, which through May 30 was about nine percent below the comparable period a year ago. Public health experts say a number of factors are driving the overall slowdown: Cuts in research spending; the time it takes to “scrub” publishable studies to avoid topics or phrases that might get researchers or the publications in trouble; and disruptions to the peer review process. Beleaguered researchers in every scientific field have less time under Trump for conducting peer reviews as they struggle to maintain funding for their own projects and labs.

“If you can’t get reviewers, there is going to be a slowdown in getting stuff published and that’s across the board,” said Nancy Krieger, a professor of social epidemiology and an American Cancer Society clinical researcher at the Harvard T.H. Chan School of Public Health. “My university had a total blockage of grant funding for a period of time, no matter what kind of research you were doing. If you were doing a clinical trial or a genetic study that had nothing to do with health equity, your lab was affected.”


All science under attack

The attack on science isn’t just affecting medical research. The National Science Foundation’s Social, Behavioral, and Economic Sciences (SBE) division, which funds more than 60 percent of all psychology, sociology and economics research, is threatened with closure. The NSF, whose budget is just a sixth of NIH’s $48.5 billion annual budget, has also ended all support for doctoral-dissertation research in archaeology, linguistics, geography and anthropology. Six weeks ago, it fired the 22 members of the agency’s board.

The Atlantic reported last month that the NSF has awarded just five social science grants this year. In a typical year, it makes about 250 grants. A White House spokesperson told the magazine’s reporter the administration will fund “advancements in hard sciences, not in ideologically driven social sciences.”

What that ignores are the advances in NSF-funded social science that help improve the nation’s health. In the 1990s, NSF financed the economics research that created major improvements in the kidney-donor-matching system. The SBE division is the primary funder of three major social-science surveys, including the world’s longest running survey of families, child poverty and economic mobility. At least nine federal agencies rely on its data.

The Trump regime’s unceasing attacks on “woke” science, coupled with its demands that prestigious journals pay more attention to quack theories, has an historical precedent. During the 1930s, Joseph Stalin promoted an obscure agronomist named Trofim Lysenko to be the Soviet Union’s top scientist based on his rejection of genetics and natural selection. Lysenko claimed acquired traits could be passed along to children. Many of the scientists who opposed his views wound up in Stalin’s Gulags. Some were shot. Russia never recovered, having yet to play a major role in the biological sciences.

The Trump regime’s science overlords, when the media come calling, have downplayed their embrace of quack science by characterizing studies of racial disparities in health outcomes, the social determinants of health and reproductive and LGBTQ health as “waste.” Their spokespersons claim “billions” of taxpayer dollars are being frittered away on diversity, equity and inclusion-motivated research.

Yet during 2025, the total number of articles, studies and commentaries mentioning those terms in their titles or abstracts (7,798) accounted for less than one-half of one percent of all studies listed in PubMed for the year (nearly 1.9 million). Given that the average NIH grant ($622,000) generates an average of about 6.5 published articles, the total amount spent on “woke” research can be roughly estimated at about $766 million — not the “billions” claimed by HHS spokespersons. “To say there is a waste of funding on this kind of research is empirically false,” Harvard’s Krieger said.

If the U.S. truly wants to reduce health care spending and make it more affordable for everyone, it needs to step up its investment in researching the causes of racial disparities in health; the role the social determinants of health (food, housing, poverty, social stress) play in driving health outcomes; and the various roadblocks subcommunities of Americans face in addressing their health needs and achieving better health.

Congress has historically defined NIH’s mission as both identifying the causes of disease as well as developing cures. It cannot come up with cures for the chronic diseases plaguing this nation unless it addresses the social factors that are its primary cause. That requires more research into those social factors, not less.

The Trump regime’s proposed rule will set back that kind of scientific research for years. That’s probably why the editors of Science issued a clarion call for political action this week, something one rarely sees in the academic literature.

“Higher education and its associations need to firmly oppose these changes, which would create a massive morale and financial problem in addition to curtailing important research,” Editor-in-chief H. Holden Thorp wrote in the editorial. “The scientific community needs to flood OMB with responses during the public comment period. Universities and associations must speak out as a united front to mobilize Congress and be ready to file lawsuits once the regulations are finalized.

“I was sympathetic to members of the scientific establishment who played it carefully during last year’s budget negotiations. Getting the budget deal done was crucial. But that was then,” he wrote. “The red light is now flashing. All hands, report to stations.”

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

When Will Democrats Bring A Fresh Vision To Our Debate Over Health Care?

When Will Democrats Bring A Fresh Vision To Our Debate Over Health Care?

As we head toward the mid-term elections, affordability has seized center stage in the health care debate, and for good reason. Americans of every class and health status are upset about the amount of money they must shell out to buy insurance and pay the extra bills that arrive after they get sick.

The ruling Republican regime is making things worse. Not only has it launched a full-scale attack on Medicaid, which covers nearly a third of all Americans, the latest White House initiative allows the insurance industry to sell low-cost plans on the Affordable Care Act exchanges that will pay only a fraction of the bills people receive after being hospitalized. If the regime gets its way, comprehensive insurance — the previous requirement for all Obamacare plans — will become unaffordable for almost everyone but the well-to-do.

Democratic Party-oriented think tanks and commentators continue to crank out proposals for making insurance more affordable. A new report from the Searchlight Institute, first reported by Jon Cohn of The Bulwark, calls for limiting private equity’s role in health care; limiting insurers’ ability to abuse prior authorization or hide profits at their wholly-owned physician practices; and wielding antitrust law to bust up hospital and pharmacy benefit manager monopolies.

Last week, Nobel laureate and substacker Paul Krugman laid out his path forward for dealing with the affordability crisis. His three-part explainer started by laying out “why universal healthcare is a desirable objective, and why some type of government intervention is essential to achieve it.”

His second installment described the ongoing Republican assault on Obamacare and its successes. But his final piece, rather than offering a bold or unique plan, or even something like the European countries to which he unfavorably compared the U.S., repeats most Democrats’ long-standing plea for including a public option on the exchanges.

A public option would allow people to buy into Medicare. Progressive groups have been advocating this for decades. The House-backed version of the Affordable Care Act in 2009 included a public option. He imagines many employers would encourage their employees to avail themselves of this new option (presumably providing them with some or most of the cost of the buy-in). “If they like what they get, which they probably would, we could transition over time to a single-payer system without forcing Americans into it,” he wrote.

Shortcomings

Krugman fails to address the virulent opposition that would be mounted against the public option by the hospital, insurance, drug and medical device industries, and the many other types of providers (nursing homes, hospice, ambulatory surgical centers, etc.) that make up the medical industrial complex. Nor does he take into account the main reason employers resist jettisoning their role: It keeps many employees from job-hopping.

Krugman assumes public anger over rising costs will overwhelm their opposition, a dubious proposition in my view even if the Democratic Party wins control over both houses of Congress and the White House. Why do I say dubious?

It is well known that health care accounts for 18 percent of gross domestic product, far more than other industrialized countries. What is less well known is the fact that direct health care provision accounts for 12 percent of all employment in the U.S. It is the largest or second largest employer in almost every city and town. In at least one recent month, the nation would have shed jobs had it not been for growth in the health care sector.

If you throw in employment in the health insurance industry, manufacturers of drugs, medical devices and durable medical equipment, and the small army of consultants, medical educators, think tankers and other health care hangers-on, about one in six American jobs flows from our bloated health care sector. Moreover, they are evenly distributed throughout the country, constituting a powerful voice in every Congressional district.

Reformers need a way to win providers — not the hospital system administrators, not the insurance company executives, not the nursing home operators; but the physicians, nurses and nurse aides, support staff, and more — to their side.

That’s why I am committed to a strategy that provides the health care sector with an off-ramp from its unproductive and wasteful ways. The system is tremendously successful at generating new technologies and treating highly complex cases. But it stinks at almost everything else that the general population needs.

It consumes more societal resources than any country on earth. It doesn’t cover everyone. Its multi-payer complexity requires enormous administrative overhead. Its specialty-driven, fee-for-service payment system delivers more pricey tests and operations than people need. It shortchanges primary care and prevention. It generates worse outcomes than other countries whether measured by longevity, infant and maternal mortality or chronic disease levels. And those lousy outcomes are extremely unfair, with minority populations suffering far worse outcomes than their white fellow Americans. (I will address this issue in my next article.)

I agree with Krugman that the Obamacare exchanges need a public option for the uninsured and for any employer that wants to join. But the details, which he doesn’t address in his article, matter. Its pricing will have to be set at a percentage somewhat larger than what Medicare pays, which is what Washington state did when it became the first state to roll out a public option in 2021 (at 160 percent of Medicare prices). Colorado and Nevada have followed suit with their own higher-than-Medicare priced public options.

Providers need a guaranteed off-ramp. They and their millions of employees can’t absorb the sudden shock to the system required by the mass migration to the public option at Medicare rates, which, according to the Medicare Payment Advisory Commission, are somewhat below breakeven rates. Therefore, in addition to creating the public option, providers need to be regulated through government-set budgets that are set at current levels and guaranteed to grow, but only at a slower rate than the rest of the economy.

Over the past several decades, health care spending has risen faster than the rate of economic growth, ballooning from 13 percent of GDP at the start of this century to 18 percent of GDP today. If budgets are allowed to grow at one to one-and-a-half percentage points above inflation (that’s about half the economic growth rate), U.S. health care spending will gradually decline to international norms.

Invest in health

What else would guaranteed budgets accomplish? It would free hospitals, physician practices, clinics and other provider organizations from the treadmill of fee-for-service medicine, where the more you do the more you make. It would free up resources to invest in the nation’s woefully underfunded primary care and behavioral health providers.

It would encourage provider organizations to invest in community outreach to underserved populations suffering from undiagnosed and untreated diseases (think hypertension, pre-diabetes, obesity, and drug, alcohol and tobacco addiction). If we treat disease before its complications set in, people will spend less time in the emergency room, where care is costliest, and often comes too late to affect the trajectory of their chronic condition.

In short, the nation’s health care system needs to transform itself into one that promotes health, not one that profits when more people get sick. The Make American Healthy Again movement has that part right. Reformers on the left should grab that page from their playbook by providing a positive vision for how to produce healthier individuals as well as a plan to reduce how much the public has to spend.


Who Will Benefit From The Latest Version Of Trump RX? Not Most Consumers

Who Will Benefit From The Latest Version Of Trump RX? Not Most Consumers

I’m a relatively healthy 75-year-old man who takes one prescription drug, a generic statin to keep my cholesterol count below the level recommended for preventing heart attacks and strokes. Those levels were recently lowered by the American College of Cardiology and the American Heart Association, which will likely lead many more Americans to be eligible for taking the pills.

Both those facts piqued my curiosity about the announcement made Monday by Donald Trump with Mark Cuban, who runs Cost Plus Drugs, at his side. They were touting adding 602 generic drugs, including statins and blood pressure control meds, to TrumpRx, the government website that directs consumers looking for lower cost drugs to Cuban’s company GoodRx and Amazon Pharmacy.

Who will actually benefit from TrumpRx, I wondered, which is touting mostly generic drugs? And how much will they actually save?

First, I looked up what I could save by buying my generic statin from Cost Plus. Under my Medicare supplemental plan, which comes through my retired wife’s former employer (a public school system), CVS Caremark manages the pharmacy benefit. The PBM requires I pay a $20 co-pay at the pharmacy counter to obtain a 90-day supply of 20-milligram rosuvastatin, the generic name for Crestor.

Cuban’s Cost Plus mail-order website says it would charge me $7.85 for a 90-day supply plus a $5 shipping fee, thus saving me $7.15 for each refill or $28.60 a year. However, Cost Plus also tacks on a $5 pharmacy handling fee. It was unclear from the website if that was part of the $7.85. If not, adding that $20-a-year into the total cost would wipe out most of any savings for me.

I then called CVS Caremark to inquire about their savings should I decide to jump off their plan for those meager savings. I use the phrase “their savings” cautiously. I have no idea if my wife’s former employer or its plan’s medical insurer hires the nation’s second largest PBM, or how much either pays to CVS Caremark. Moreover, how much the PBM profits from the ultimate payer — the taxpayers behind the public employee retirement system — is unknown. So is the price it pays the generic manufacturer and any other middlemen that may have stuck their hands into the honey pot.

In any case, the call center operator told me the total cost to the PBM was $60.86 every 90 days. But that was before I paid $20 every three months at the pharmacy, so the cost reduction for everyone else would be about $164 a year, at least six times more than me. As noted above, how those savings would be divvied up between the PBM, the medical insurer and the employer-payer is safely contained in someone’s black box.

Will it benefit the uninsured?

How about the alleged major beneficiaries of TrumpRx — the uninsured who have to pay for any health care out of their own pockets? Their ranks are growing daily due to this year’s massive increase in rates for Affordable Care Act plans triggered by the regime’s handmaidens in the Republican-run Congress, who allowed the Biden-era increase in plan subsidies to expire.

When ACA-insured, the people dropping plans paid nothing for their cholesterol and blood pressure control medications, even if their plan had deductibles. All preventive services rated “A” or “B” by the U.S. Preventive Services Task Force must be offered free of charge under the ACA. Statins are rated “B.”

But under TrumpRx, those dropping coverage (or those that never had a plan in the first place) will have to pay the full cost. If they turn to Cost Plus Drugs, that would be at least $52 a year with maybe an additional $20 for the pharmacy fee.

Of course, both groups could run into trouble when renewing their prescriptions if they no longer have or never had a primary care physician. When signing up for Cost Plus Drugs, which I did today, I had to provide the name and contact information for my prescribing physician.

Even if they can get past that hurdle, people who are uninsured are usually pinching pennies. They no longer have a primary care physician. They don’t go in for routine checkups, which might identify when they have high blood pressure or dangerously elevated cholesterol. They are less likely to adhere to diets with less salt and less processed foods, which promote better heart health.

The ACA had it right. Drugs that have been proven to prevent serious diseases should be entirely free of charge to the consumer/patient. They are a wise investment that pays off in reduced hospitalizations and reduced complications from chronic diseases, which in turn reduces long-term health care costs. Plans like my supplemental should eliminate their co-pays entirely for such drugs, especially when they are generics like most statins and blood pressure meds.

TrumpRx sets up a financial barrier to access. It will decrease the population taking these important interventions. It is a public relations stunt designed to look like the regime is doing something about the high cost of drugs, which is entirely driven by the cost of new drugs coming to market and the high prices on those that remain on patent, not the extra fees PBMs tack onto prices.

Paying for value

One final thought: The regime is stepping up its pressure on European countries to raise their drug prices, which are substantially less than what is paid in the U.S. Why? Other advanced industrial countries are effective drug price negotiators. They refuse to pay more than the carefully calculated medical value of a prescription.

The U.S., on the other hand, insists that foreigners pay their “fair share” for innovation instead of using the same negotiating and value measurement tactics. Big Pharma’s argument — that the high cost of drugs is driven by the high cost of research and development — never held much water and has grown increasingly shallow given how much innovation has moved to China in the wake of the regime’s immigration policies and gutting of National Institutes of Health funding.

This Trump regime’s attempt to impose so-called reference pricing is, in essence, a strategy to maintain as much revenue as possible flowing to Big Pharma. It provides no long-term brake on rising costs. The U.S. would pay slightly less; other industrialized countries would pay slightly more; less developed countries would continue to go without the latest therapeutics; and the drug industry would maintain the status quo on profitability.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News


Kennedy's CDC Chief Censors Research Proving Benefits Of COVID Vaccination

Kennedy's CDC Chief Censors Research Proving Benefits Of COVID Vaccination

Previous administrations, including Donald Trump’s first, usually upheld the ideal that the Food and Drug Administration and other federal health agencies would adhere to the “gold standard” for research.

For the FDA, whose jobs include the approval of new drugs, vaccines and medical devices, the gold standard meant requiring rigorous clinical studies to prove that experimental products were both efficacious and safe. That usually means a manufacturer has to submit at least two trials, both of which are placebo-controlled and double-blinded (neither patients nor their physicians know if they received the real thing). Patients in the trials are randomly assigned to one group or the other — hence its name, the randomized controlled trial or RCT.

The Center for Disease Control and Prevention is charged with monitoring the extent and seriousness of health threats in the U.S. Its gold standard is different because it involves epidemiological studies, where researchers measure the extent of a disease and its outcomes in the population by mining medical records or conducting surveys drawn from well-matched cohorts. It often relies on data collected by state and city public health agencies.

In recent weeks, the press has reported that both agencies’ staff scientists have had studies withdrawn from medical journals (the FDA) and an in-house publication (the CDC). On Tuesday, the New York Times reported that “In October, (FDA) scientists were directed to withdraw two Covid-19 vaccine studies that had been accepted for publication in medical journals. In February, top F.D.A. officials did not sign off on submitting abstracts about studies of Shingrix, a shingles vaccine, to a major drug safety conference.”

Two weeks ago, the Washington Post and other publications reported top officials at the CDC refused to allow publication of a study showing the effectiveness of the Covid vaccine in reducing hospitalizations. It had been scheduled for publication in Morbidity and Mortality Weekly Report, the agency’s well-regarded in-house journal.

Jay Bhattacharya, who runs the National Institutes of Health and is the interim head of the CDC, defended his decision to deep-six the study in a a op-ed. “I raised specific concerns about the statistical methodology chosen for the study in question,” he wrote. “These concerns about the test-negative design used go directly to the validity of the study’s conclusion.”

I’ll have more to say on test-negative design in a moment.

A new journal for CDC

Bhattacharya also announced plans for the agency to launch a peer-reviewed journal “to elevate scientific rigor across all CDC publications,” he wrote. “Peer review remains the gold standard because it subjects findings to independent scrutiny, forces transparency about limitations and strengthens confidence in the results.”

The peer review panels for this new journal, when chosen, will definitely warrant “independent scrutiny.” Should they follow in the footsteps of how the CDC has remolded its vaccine advisory committee, it should provide plenty of grist for the Retraction Watch, which monitors medical and scientific journals for published retractions. The RW website database lists tens of thousands of incidents where peer reviewed failed to catch factual errors, deliberate falsifications and other misfeasance and malfeasance in the academic journal publication process.

I have served on several peer-review panels. I will never forget the note I received from one author after I made a number of pointed suggestions for improving his study’s conclusions. He thanked me for giving him one of the most comprehensive reviews he had ever received, one that was very helpful in improving the manuscript.

I don’t offer this anecdote to pat myself on the back. It confirmed something I’ve often heard said about peer review. A better name for the process might be “colleague review,” or “friendly review,” or even “ideological fellow-traveler review.” It would be out of character (and I will be pleasantly surprised) if the Trump regime’s CDC sets a higher standard.

“I cannot recall CDC stopping an MMWR report in the publication phase after scientific clearance and editorial review.” — Michael Iademarco, who directed the CDC center that publishes MMWR from 2014 to 2022.

Bhattacharya, who trained as an economist and physician at Stanford, has never worked as an epidemiologist or as a practicing physician. But he emerged as an expert during the Covid pandemic by co-authoring the Great Barrington Declaration, which called for allowing the general population to opt out of vaccination while adopting special measures to protect seniors, who were most vulnerable to the disease. The one country that tried that approach (Sweden) quickly abandoned it due to mounting mortality among its working-age population.

'Test-Negative' Epidemiological Research

His demand for something better than “test-negative” design sounds to me like obfuscating jargon that could be used to call into question most epidemiological research. “The core problem” with that approach, he wrote, “is that, to measure the effectiveness of a vaccine in keeping people out of a hospital (for instance), this method throws away all data about people, vaccinated or not, who are never hospitalized. Instead, it replaces data with unverifiable assumptions, leading to bias. Factors such as prior infection, behavioral differences and who shows up for care can all skew results in ways that are hard to adjust for.”

Yes, all epidemiological studies that compare outcomes among two groups that haven’t been randomized have unmeasured factors that might skew the results. And there’s lots of junk science in the medical literature that makes no attempt to adjust results for unmeasurable factors. Here’s one: Martin Makary’s most recent book (he now runs the FDA) cited a study that “proved” fluoride reduces intelligence by comparing the average IQ scores in two Canadian communities, only one of which had fluoridated water (and slightly lower IQ scores among its school age children).

But most studies, especially those published in reputable journals, attempts to adjust for those unmeasured factors. The Times in its story pointed out that the “test-negative” design has been used in numerous CDC studies over the years and is well accepted in the peer-reviewed medical literature. It was used in a 2021 study on Covid vaccine effectiveness that was published in the New England Journal of Medicine, and in numerous peer-reviewed studies published in journals like JAMA Network Open, The Lancet, and Pediatrics.

The Post, in its story two weeks ago, quoted Michael Iademarco, who directed the CDC center that publishes MMWR from 2014 to 2022, which included Trump’s first term in office. “I cannot recall CDC stopping an MMWR report in the publication phase after scientific clearance and editorial review,” he said.

That is, not until contrarians like Bhattacharya and Makary and the anti-science, anti-vaccine Robert F. Kennedy Jr. took over the agencies that are charged with protecting the public’s health. Now, science is whatever they say it is.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

Kennedy's Promotion Of Unproven Peptides Undermines Science And Public Safety

Kennedy's Promotion Of Unproven Peptides Undermines Science And Public Safety

Journalists are often accused of using the following aphorism to determine the newsworthiness of a story: “Once an accident. Twice a coincidence. Three times? A trend. Go for it!”

Using that habit of mind to drive journalism is a bad idea. People will be misinformed. Using it to drive the practice medicine is worse because people will get hurt.

This past weekend, I read a recent story in The New Yorker about “the seductive world of unapproved peptides,” written by Dhruv Khullar, an outstanding medical journalist. The physician-writer visited several clinics run by board-certified physicians pushing these protein snippets on gullible people looking to heal ailing muscles, improve memory and live longer lives, among other alleged benefits.

The testimonials offered by physicians promoting various peptides defied every standard of medical evidence developed since Founding Father Benjamin Rush gave up bloodletting. Charleston, South Carolina’s Craig Koniver, trained in family medicine, called one peptide used for tissue healing (BPC-157) “supersafe” and said “almost everyone I could think of” will benefit from it. A few paragraphs later, he says, “I’m not a big vaccine guy. A lot of them don’t have the data.”

What’s the data behind BPC-157? There are exactly two clinical trials for that peptide in the federal government’s clinical trials database. One is an early-stage safety trial of unknown scope and status that is taking place in Tijuana. The second is an efficacy study based in Shenzhen, China, which is still recruiting patients. Vaccines, on the other hand, have undergone extensive testing and they’ve gained FDA approval, which means there are reams of data documenting both their safety and efficacy.

Koniver goes on to say “anecdotal data means a lot to me. Two days after a vaccine, someone has a stroke. Two days later they’re dead. … You see enough of that, it makes an impression.”

There’s no shortage among his 1,000 patients, who pay $15,000 a year for the services of his concierge medical practice (it doesn’t take insurance), willing to attest to peptides’ benefits. After all, wait long enough and most tissue tears eventually heal. Koniver (is a Charles Dickens doppelganger now the resident fact-checker at The New Yorker?) has 6,000 people on his waiting list.

Many of the people lining up to spend their hard-earned money on peptides may have heard the siren call of the ultimate peptide guru, Robert F. Kennedy, Jr., who sits atop the Health and Human Services Department. He frequently claims he benefited from injecting peptides to cure injuries sustained during body-building exercises.

He appeared earlier this year on the Joe Rogan podcast (the world’s most popular with 11 million listeners). Rogan frequently touts peptides on his show. The field also received an unexpected boost from the FDA’s approval of semaglutide (Ozempic, Wegovy, Zepbound), a peptide for diabetes and weight loss. If that one works, won’t they all?

Semaglutide is the exception, not the rule when it comes to data on peptides. There is almost no evidence beyond individual anecdotes that most of the peptides now in circulation, mostly produced by compounding pharmacies, actually benefit patients or are safe.

Earlier this year, Kennedy removed the limited regulation of unapproved peptides that had been put in place during the Biden administration because their manufacturers failed to submit data to the FDA proving they could be safety injected in patients. The Kennedy reversal hurled peptides back into the regulatory vacuum enjoyed by dietary supplements, where the only rules that apply involve purity (does it contain what it claims to contain) and a ban on making medical claims (which is routinely violated by industry advertising).

For a dispassionate dissection of Kennedy’s views on peptides as expressed on the Joe Rogan podcast, watch this YouTube video by Matt Kaeberlein, a professor pathology at the University of Wisconsin Medicine and co-founder of UW’s Health Aging and Longevity Research Institute. “There are numerous cases out there where people have been harmed by peptides … Nobody has come forward with any good data on the safety of these peptides.," says Kaeberlein.

Good data on peptides, whether for efficacy or safety, requires someone conducting randomized clinical trials that test whether the products are better than a placebo or the current standard of care. The tests need to be in a sufficiently large population to show statistical significance in any outcomes differences between the two groups. Absent clinical proof of efficacy in such trials, there will only be the risk of harm or unpleasant side effects.

The Biden administration upheld evidence-based medicine when it required most peptides undergo such tests. The Trump administration via Kennedy opted instead for allowing money-hungry physicians and compounding pharmacies to conduct what amounts to an uncontrolled science experiment on gullible Americans, where no one takes a measure of the outcomes except the individuals and families who will be harmed both physically and financially.

The peptide craze is following the same trajectory of the anti-vaccination movement (also championed by Kennedy); the evisceration of National Institutes of Health research into the many social causes of disease; and the degradation of the Centers of Disease Control and Prevention’s ability to promote population health. It is anti-science, pitch perfect for a society addicted to addictions, promoted by someone who admits he once snorted cocaine off a toilet seat, who now jabs needles in his body in the evidence-free pursuit of faster healing and better health.

Peptide proponents claim it is their right to try unapproved substances based on claims made by family, friends,or their concierge physician. It’s my body. I willingly take the risk. Whom else does it harm?

Actually, everyone. Who pays when you end up in the hospital and wrack up huge treatment bills? Two people fell desperately ill during a Las Vegas “anti-aging” event after injecting peptides and had to be intubated. Widespread allergic reactions to the shots, some of which were life-threatening, forced regulators in Australia to issue a safety alert. Health Canada has issued a warning that unauthorized peptides can cause blood clots and liver and kidney damage.

The U.S. used to have a regulatory agency that the rest of the world awarded a gold medal for how to manage the entry of medical products into the marketplace. Today, under this government, it isn’t even in the race.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

How Trump Republicans Cut Down The Child Tax Credit And Drove Up Child Poverty

How Trump Republicans Cut Down The Child Tax Credit And Drove Up Child Poverty

A few days before President Trump’s second inauguration, Republican Senator Josh Hawley of Missouri gave an impassioned speech on the floor of the Senate calling for a dramatic increase in the child tax credit.

The Biden administration’s first pandemic relief bill had temporarily lifted the maximum credit to $3,600, which had the salutary effect of dramatically lowering the childhood poverty rate to five percent, the lowest ever recorded. But the expiration of the increase after 2022 caused the child poverty rate to surge back to previous levels – more than 12 percent. Unless the new GOP-run 119th Congress acted, the credit would drop to $1,000 from $2,000 due to a sunset provision stuck in Trump’s first corporate tax giveaway, which passed in 2017.

“For every Republican who has hailed the new working-class majority that President Trump has delivered, now is the time to deliver,” Hawley proclaimed. “Delivering results in this body is the acid test.”

Last July, Hawley’s resolve disappeared faster than Washington’s cherry blossoms in spring. He voted, along with all but five members of the GOP, for the $2 trillion tax giveaway to corporations and the rich known as the One Big Beautiful Bill. It did not include his $5,000 child tax credit. Instead, Trump and the GOP, in their search for revenue to offset a tiny fraction of the tax cut, limited the increase in the child tax credit to $200, which didn’t even make up for the past four years’ inflation.

Support for child tax credit has long been a bipartisan affair. It has received renewed attention from the GOP in recent years with the political ascendancy of the Christian right. Groups like Susan B. Anthony Pro-Life America, Eagle Forum, and the National Association of Evangelicals see it as government support for natalism, a part of their anti-abortion and family values agenda. Some Christian Nationalists support it because it provides support for “biblical” families where men work and women focus on cooking, cleaning and raising children.

Of course, few families in today’s economy, especially those in the bottom half of the income distribution, can afford to raise children with a single wage earner. Both parents work in 66 percent of the 33 million two-adult households with children (this data comes from the Bureau of Labor Statistics for 2024). In the 10 million households with single parents (three-quarters headed by women), 76 percent hold down full- or part-time jobs. For single fathers with kids, it is 85 percent.

Clearly, most of the parents taking the child tax credit (CTC) at tax time are more likely to spend the extra cash on day care as support their desire to send a young mother back to the kitchen. But the fact that it is a cash grant allows each family to make that choice and gives politicians on both sides of the aisle arguments for supporting its expansion.

Recognition of the underlying economic realities led Hawley to call for a big increase in the CTC. He also wanted it extended to families expecting children, and included in every paycheck throughout the year, not given as a lump sum at tax time. People living paycheck to paycheck don’t need an enforced savings program, they need the cash now.

How would he accomplish that? By basing the credit not just on federal income taxes, which are low to non-existent for most low- and modest-income families, but also on Social Security and Medicare payroll taxes, which take 7.65% out of every dollar they earn.

Democrats have very different reasons for supporting a big expansion of the CTC. They see it as an essential part of the social safety net, and a component of a growing movement to create a guaranteed family income in the U.S., which has strong backing from urban mayors. It also could help offset a small part of the more than $1 trillion in cuts to food assistance and health care contained in the Trump administration’s One Big Ugly Bill.

The roots of income supplements

The Republican Party’s support for income supplementation traces its roots to the late 1960s when Daniel Patrick Moynihan, the centrist academic then serving as President Nixon’s chief domestic policy adviser, proposed a negative-income tax for low-income families with children. He argued that providing string-free cash to poor families was more empowering and administratively simpler than forcing them into the hands of separate government bureaucracies doling out housing, food or welfare subsidies.

Moynihan’s Family Assistance Plan also tied benefits to work – a forerunner of today’s GOP imposition of work requirements in Medicaid and the Supplemental Nutrition Assistance Program (colloquially known as food stamps, although today it comes in the form of a debit card). Such requirements never lead to alleged shirkers seeking work. Rather, they erect bureaucratic barriers that keep underpaid workers from receiving benefits that by law should be theirs.

The first cash subsidy tied to work became law in 1975 when Congress passed and President Ford signed the Earned Income Tax Credit (EITC), whose maximum benefit today is twice as large as the CTC. Later, after becoming the Democratic Senator from New York, Moynihan continued to push for a CTC to provide extra support for low-income families with kids. Though President Reagan endorsed the idea, nothing came of it during his or George H.W. Bush’s time in office.

House Speaker Newt Gingrich included the CTC in his mid-1990s Contract with America, which became law with President Clinton’s signature in 1997. The original $400 credit was gradually increased by succeeding Congresses (again with bipartisan support) to keep pace with inflation.

Things changed in the current MAGA-controlled Congress, however. In last year’s massive tax break bill, which passed six months after Hawley’s fiery speech, most of the tax breaks again went to the wealthy and corporate America. The GOP failed to include Hawley’s $5,000 credit. Instead, it increased the CTC to $2,200, which in inflation-adjusted dollars is less than where in stood when Trump left office in 2021. Hawley voted yes on the bill, flunking his own acid test.

The CTC’s flaws left unaddressed

The One Big Ugly Bill also left each of the CTC’s well-documented flaws intact. An estimated 21 million low-income households do not qualify for the maximum credit because they don’t earn enough money. An estimated 2 million children live in households that receive nothing at all because they make so little they have no taxes to offset.

The GOP also ignored Hawley’s plea to restructure how payments are made. The money is still doled out at tax time in a lump sum, not over the course of a year when it would be most helpful in paying monthly bills or buying school supplies and winter clothes for their kids.

“A check at tax time is a very paternalistic approach to policy,” said Jane Waldfogel, a professor of social work at Columbia University. “We’ll enforce savings, and then, once a year, we will give you a check you can use for something big like furniture for the kid’s bedroom or getting your car on the road.”

Her recent book, “Child Benefits,” analyzed child support programs in the 38 countries belonging to the Organization for Economic Cooperation and Development. “All the wealthy countries have them,” she said. “In some countries, they’re scaling them back for wealthy families. Perversely, in the U.S., we’re doing the opposite. We now include all the middle- and high-income families but exclude the lowest income families.”

Pilot projects proliferate

This disparity, and the lack of federal action amidst massive cutbacks in safety net programs like Medicaid and food assistance, has led many local governments and some states to experiment with their own cash assistance programs, many with help from charitable foundations. Over 150 local officials belonging to Mayors for a Guaranteed Basic Income report there are more than 200 pilot projects underway in the U.S. They offer low-income residents as much as $1,000 a month to supplement their meager incomes.

One in Chicago and Cook County where I live was launched in 2022. It used $42 million in Covid relief funds to provide $500 a month to 3,250 households for two years. A survey completed early last year found 75% of recipients reported feeling more financially secure; 94% said they used the program to deal with financial emergencies; and 70% said the program improved their mental health. Based on those findings, Cook County government last November appropriated $7.5 million to continue the program for another year on a more limited basis.

The Family Health Project in the Boston area focuses on low-income, single, expectant mothers with children or about to have their first child. Since 2022, it has provided $400 a month for three years to two cohorts of 15 mothers. The cash arrives on a debit card each month on the same day as their baby’s birth. “It underscores that this is about the baby, not about the mom,” said Joe Knowles, the CEO of the non-profit Institute for Health Metrics, which helps hospitals develop the community needs assessments required by the IRS to maintain their non-profit status.

He began the Family Health Project after speaking with Jeffrey Madrick, the author of The Invisible Americans: The Tragic Cost of Child Poverty. Said Knowles: “In it, he posits a direct cash benefit program is a way to begin to control poverty and help make it go away. It turns out that poor people aren’t lacking motivation, intelligence, or integrity or know-how. Poor people lack money,” he said. “A big piece of this is trust philanthropy. Don’t give mom services. Give her the money and she’ll know what to do in almost all cases.”

His small organization tracks the results through in-depth interviews with the mothers. When asked how they spent the money by relationship manager Kelly Journey, the mothers invariably say it is on things like diapers, toys, and clothes. “The biggest thing I see is that these moms get the assurance that somewhere someone believes they’re going to be a good mother. It’s powerful,” she said.

There is little question that extra cash helps the financial, physical and mental well-being of adults caring for small children. A research review conducted by Megan Curran of Columbia University in late 2022 found the expanded CTC, which had just expired, was mostly spent on basic needs. It reduced food insecurity and did not lead to less employment – a frequent charge by right wing think tanks opposed to the program.

But whether the CTC makes a difference in the life of the baby remains an open question. In recent years, researchers like Jack Shonkoff, who runs the Center on the Developing Child at Harvard School of Education, and advocates like former Kaiser Permanente CEO George Halvorson, whose book, Three Key Years, was published by the Institute for InterGroup Understanding, have focused on the importance of the first three years of a child’s life in determining their long term prospects. Income support in the form of direct cash transfers, according to Shonkoff’s Pre-natal-to-3 Policy Impact Center’s literature review, “improve household resources, child health and development, and parent health.”

A flawed study

But in the largest randomized controlled trial testing that claim, researchers found few positive impacts after four years of monthly payments to mothers of small children. The study, called Baby’s First Years and partially funded by the National Institutes of Health, recruited 1,000 mothers and their newborns from hospitals in Minneapolis/St. Paul, New Orleans, New York and Omaha. The researchers provided 400 moms with a monthly debit card worth $333 and 600 moms with a card worth $20.

The trial lasted four years, with recruiting beginning in 2018 and ending in 2023. The follow-up measured maternal depression, anxiety and body mass index, and whether the babies in families with larger cash infusions were more likely to develop language skills or avoid developmental delays. The researchers even used EEGs to measure brain activity, which can signal greater cognitive development.

In each case, there was little difference between the two groups. “The families with higher cash subsidies spend more on their children, on books, toys, and things like that,” said Lisa Gennetian, a professor of public policy at Duke University. “They’re reporting they spend more time with their children, reading, playing, activities.”

But, she said, “the cash otherwise is not having a lot of impact on family life. No impacts on mom’s subjective well-being, their happiness, their lifestyle satisfaction, their emotional well-being. We’re not finding impacts on measures of material hardship like food or housing security. We’re not finding this modest amount is changing things for family,” she told me in a telephone interview.

The researchers admit several issues may have confounded the study. First and foremost, the Covid pandemic struck in the middle of the study period, which disrupted everyone’s life and low-income people most of all. In addition, the amount offered the new moms was small – about equal to the expanded CTC – which mothers in both arms of the trial received. The fact that everyone received some money – there was no null set – may have biased the control arm participants toward being grateful for what they’d been given, no matter how small, and that may have affected their self-reported results.

“Everyone in all the studies tells you how helpful the money has been,” said Gennetian. “It increases autonomy and agency. That’s what we’re hearing from our families.”

One of the lead authors in the study, Greg J. Duncan, a distinguished professor in the Education Department at the University of California, Irvine, says the next follow-up with the children and their moms will begin in July with results expected in 2029. He also co-authored a National Academies study released two years ago that reviewed all policies aimed at reducing intergenerational poverty.

That report concluded that other forms of income support had a far greater effect on improving the life prospects of children raised in poverty than the limited CTC. “We had studies backed by strong evidence that showed when kids and their families received support from the earned income tax credit, Medicaid and SNAP, the kids benefited in the long run. The CTC has not yet shown long-run improvements.”

He hopes the next follow-up on Baby’s First Years will. He recalled how one Minnesota mom took pictures of a winter coat she purchased with the money. Before that, her child had piled on sweaters and was socially castigated for not having money in her family.

Getting a coat “won’t improve her vocabulary scores,” Duncan said. “Providing a normative childhood for their kids isn’t the kind of thing that changes electrical activity in the brain.” But it might improve relations between the child and the mother and lead to better relations with their peers. “That might support differences at age 8 and 10,” he said.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News


Will Measles Surge And Ethical Conflicts Stop This Anti-Vaxxer Becoming Surgeon General?

Will Measles Surge And Ethical Conflicts Stop This Anti-Vaxxer Becoming Surgeon General?

President Donald Trump — his eye on crumbling approval ratings and the growing likelihood that he’ll face a Democratic House after the mid-term elections — is reportedly souring on the Make America Healthy Again show.

He has postponed appointing someone to run the flailing Centers for Disease Control and Prevention, where the sands seem to be shifting. Its interim director Jay Bhattacharya, who also oversees the shrinking National Institutes of Health, on Wednesday morning told what’s left of the CDC staff, “I think it is vital that every kid in this country get the measles vaccine. Absolutely vital.”

In the wake of her confirmation hearing last month, various media reports claimed Casey Means’ nomination to become the nation’s next Surgeon General is in trouble. Sen. Bill Cassidy (R-LA), a pediatrician, backs vaccines and she didn’t. Sens. Susan Collins (R-ME) and Lisa Murkowski (R-AL), the GOP’s designated fence sitters, said they still have questions. Sen. Thom Tillis (R-NC), who is retiring, told the Associated Press he’s leaning against voting for Means should her nomination reach the full Senate.

Yet, given anti-vax sentiment within MAHA and the group’s role in grass roots GOP politics, it’s way too soon to count Means out.

Who is Casey Means? She made her fortune as co-owner of Levels, which sells an app for continuous glucose and blood monitoring. The firm’s subscription plans (costs range from $288 to $1,999 annually) are marketed primarily to the worried well to “help you fuel better and feel more balanced.” (That cheeky description comes directly from the company website.)

Two years ago, the FDA approved the over-the-counter sale of a glucose monitor that Levels promotes for its corporate partner, Dexcom. That company used a regulatory process for approving medical devices that doesn’t require submission of clinical trial data proving that it leads to better outcomes.

Dexcom also does business with Means’ brother Calley, a top health care adviser to the Trump administration. He is co-owner of Truemed, which encourages consumers to use health savings accounts to buy supplements, fitness equipment, red light therapy and saunas from its manufacturing partners.

A year ago, just two months before Casey Means was nominated for surgeon general, the Means siblings appeared at a supplements industry trade show. Their message, according to an Associated Press account of the Natural Products Expo: The goals of the Make America Healthy Again movement will help your bottom lines.

The head of MAHA’s political action committee, which pushes for anti-science policies in state legislatures and nationally, told the same conference: “It blows my mind that I'm going to watch the Republicans carry the supplement industry and the holistic health industry and chiropractors and the acupuncturists into the promised land.”

The supplements and wellness industries do not need another Moses, although they could get one in Means. Those fast-growing, largely unregulated businesses took up residence in the land of milk and honey when the late Sen. Orrin Hatch, a Republican from Utah, shepherded the 1994 Dietary Supplement and Health Education Act through Congress. That law officially exempted supplements from meeting FDA efficacy requirements, and limited safety oversight to manufacturing purity, not prevention of physical harm. Even the good manufacturing practices guidelines allowed under the bill are non-binding.

No wonder the supplements industry grew from 4,000 products when the DSHEA passed to about 90,000 today. It has become a $70 billion-a-year industry in the U.S. — twice the size of the European Union, which has about the same number of people.

Today, grocery stores dedicate entire aisles to supplement sales, as do a few large retail chains like GNC (General Nutrition Corp., now owned by the Harbin Pharmaceutical Group of China). Analysts estimate the industry will grow by 50% over the next five years.

Conflicts-of-interest disqualify thee, but not me

In most accounts of her career, Means lambasts the medical profession for being in bed with the pharmaceutical industry. She dropped out of her medical residency in otolaryngology (ear, nose and throat doctors), claiming the field was rife with conflicts of interest.

She says (with some justification) that many of its practitioners prefer seeing more patients needing their skills than focusing on prevention. Like Kennedy, her champion, she repeatedly attacks the drug industry, vaccine makers and mainstream medicine for their conflicts of interest.

Yet the MAHA movement and the Trump regime ignored her conflicts of interest (and her brother’s) before appointing them to high government positions. Casey Means’ financial disclosure, released last September, showed that over the past five years she received “newsletter sponsorship and partnership fees (of) $12,000 from herbal remedies firm Apothekary; $27,431 from algae supplements company ENERGYbits; $16,461 from fiber supplements company Florasophy; $27,000 from probiotics company Pendulum Therapeutics; $46,000 from supplements company Pique; $536 from prenatal vitamin company WeNatal; and $16,104 from basil seed supplements company Basil Seed Works. Means received a total of more than $130,000 in sponsorship fees from supplement company Amazentis, including a $55,000 book tour sponsorship.”

Mehmet Oz, who runs CMS for the Trump regime, and top adviser Calley Means have also profited from their ties to the supplements industry.

The false promises of most supplements

The supplements industry is a case study in how to use marginal, company-sponsored science, heavy advertising and political muscle to peddle useless products to the American people. As more than one industry critic has pointed out, the industry is responsible for Americans having the most expensive urine in the world.

Their lobbyists have successfully fought every legislative attempt to impose either efficacy or safety requirements on supplements — the standard applied to drugs. Supplement makers are not required to submit placebo-controlled clinical trials to the government. Yet many in their advertising make carefully worded statements about health benefits that to the average consumer sound like it has been scientifically proven, something that the FDA is supposed to prevent.

Prevagen — widely advertised as improving “brain health” — is the poster child for this improper marketing and failed regulatory oversight. The FDA began raising safety concerns as early as 2007 and sent its first warning letters to Quincy Bioscience, its maker, in 2012. The Federal Trade Commission and New York State filed suit in 2017 to stop Prevagen’s alleged illegal marketing. It took seven years of litigation before a federal court finally issued an injunction against the company to stop making the claim that Prevagen improved brain function.

Despite that 2024 ruling, late night television is still filled with Prevagen ads aimed at seniors and the worried well wanting to stave off dementia. Today, instead of the company making the claim, they use older adults testifying that the product helped them.

In defending her nomination, administration spokespersons have touted Means’ stellar academic credentials. Means is a 2014 graduate of Stanford Medical School. She received advanced training in otolaryngology, her specialty, at Oregon Health & Science University.

But she dropped out in 2018 to launch her wellness career after seeing how little organized medicine did to prevent the need for surgery. She launched Levels a year later with $12 million in venture capital funding. By 2024, she was deeply involved with Kennedy’s presidential campaign and co-wrote with her brother a New York Times 2024 best-selling book called Good Energy: The Surprising Connection Between Metabolism and Limitless Health.

Jumping in front of the MAHA parade

As the New Yorker reported in its book review, the publicity blitz for the book included appearances on the Joe Rogan podcast and Tucker Carlson show on Fox. She told Carlson her sacred texts included the Bible and Ayn Rand, clearly an attempt to endear herself to the Christian Nationalist and Libertarian wings of the 2024 Trump coalition.

She allied herself with Kennedy, too, although many in the MAHA movement remained skeptical of her blind ambition. “Nicole Shanahan, who was Kennedy’s running mate during his 2024 Presidential bid, posted on X that ‘there is something very artificial and aggressive about them (referring to both Casey and Calley Means), almost like they were bred and raised Manchurian assets’,” the review noted.

Her ties to Kennedy, himself a late convert to Trumpism, led to her nomination to become the nation’s 22nd Surgeon General. At 38, she would be the second youngest person to hold that post after Dr. Vivek Murthy during President Obama’s first term.

Like some previous Surgeons General, she would come to the office without the government or professional experience that would qualify her to supervise the 6,000-plus uniformed physicians and other public health professionals who serve in government agencies. But unlike most previous Surgeons General, she has eschewed becoming a practicing physician, choosing instead to engage in entrepreneurship, part-time teaching, political advocacy and politics.

Often called the nation’s doctor, Surgeons General usually make their mark by focusing on a single public health problem. Many have been steeped in controversy.

In 1964, Luther Terry ignored tobacco industry opposition to issue the first official warning that cigarette smoking causes cancer. During the Reagan presidency’s AIDS crisis, which the White House ignored for nearly his entire two terms in office, C. Everett Koop mailed a brochure to every American household explaining the viral (not moral) causes of the disease and how to prevent it. In the 1990s, Joycelyn Elders focused on sex education and adolescent sexual health, making her a target for conservative culture warriors.

Means, during her prolonged nomination process (it was put on hiatus last year during her pregnancy), has sought to make the fight against chronic illness the centerpiece of her tenure — a worthy endeavor that would require taking on (at the least) the processed food, chemical, and agriculture industries. During her opening testimony at her confirmation hearing last month, she blamed Americans’ “ultra-processed diet, industrial chemical exposure, lack of physical activity, chronic stress and loneliness, and overmedicalization” for making the U.S. “the most chronically ill high-income nation in the world.”

She wouldn’t be the first to express those concerns. Richard Carmona under George W. Bush and Regina Benjamin under Barack Obama also targeted chronic disease, which they blamed on rising obesity, unhealthy diets and a lack of exercise. Nor is there much controversy in that stance. Sen. Bernie Sanders, the Vermont independent socialist who caucuses with Democrats, praised that aspect of her presentation during the hearing.

A vaccine two-step in the offing?

But her nomination is in trouble for one reason and one reason only: Casey Means refuses to separate herself from the Robert F. Kennedy Jr.-led war on vaccines.

At last month’s hearing, she refused to directly endorse the childhood MMR vaccine (measles, mumps, rubella) despite a multi-state measles outbreak, triggered by the declining vaccination rate, that has sickened thousands and taken at least two children’s lives. Instead, she called for parents to discuss the issue with their doctors.

“You’re the nation’s doctor,” Sen. Cassidy, chairman of the Senate committee, said. “Would you encourage her to have her child vaccinated?”

“I’m not an individual’s doctor,” she replied. “Every individual needs to talk to their doctor before putting a medication in their body.”

When Sen. Tim Kaine (D-VA) pressed her to confirm that the flu vaccine saved lives, she demurred.

“This is an easy one, doctor, this is an easy one,” Kaine said.

“I support the CDC guidance on the flu vaccine, and I will always be working with the CDC and ACIP,” she replied.

That would be the same ACIP that was hand-picked by Kennedy; that has scaled back its childhood vaccination recommendations without offering scientific justification; and which a New York federal court last week ruled was illegally appointed.

Means also refused to rule out vaccines as a cause of autism, instead calling for more research because science is never settled. But at the present moment, the scientific literature not only overwhelmingly rejects that thesis, but the first major study suggesting there was such a link, which was published in the prestigious Lancet, has been retracted for data fraud with its primary author banished from the practice of medicine in Great Britain, his home country.

Is Dr. Means unqualified to become the next Surgeon General? You betcha. Will she? Betting markets reportedly put her chances at less than 50 percent, with a sharp drop after last month’s hearing. Given the GOP’s latest election losses, including in Trump’s hometown of Palm Beach, they’re probably even lower today.

I’m usually in the Yogi Berra camp when it comes to predictions, but I’ll go out on a limb here. I predict Means will make private assurances to the reluctant four-some in the GOP-controlled Senate and win confirmation to become the least qualified Surgeon General since the post was established in 1871.

The 38-year-old wellness influencer and entrepreneur, who doesn’t practice medicine, even in her spare time, is nothing if not ambitious. All she has to do is follow Bhattacharya’s lead and do an about face on some aspect of vaccine policy. The big guy and the GOP-controlled Senate — desperate for some good news on the electoral front — will notice.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

Trump and Hegseth

Iran War's Explosive Costs Could Finance Health Care Coverage For Millions

The Pentagon is asking the White House for an additional $200 billion to fight the president’s ill-conceived war in the Middle East.

While it’s unclear from the initial news reports whether this is a one-year or multi-year appropriation, the size of the request suggests this war is going to drag on a lot longer and involve far more manpower and firepower than President Trump and Secretary of Defense Pete Hegseth have let on. The now three-week-old war of choice has already left 13 soldiers dead and more than 140 wounded. It has already cost over $12 billion, according to reported estimates.

Let’s put that cost and this latest request in perspective. The $12 billion already spent is enough to have extended the Affordable Care Act subsidies for close to six months.

Instead, over two million or nine percent of people in ACA health insurance plans last year dropped them for this year (the first without the expanded subsidies) because they couldn’t afford the huge increase in their premiums, according to a new survey released yesterday by KFF, a health care think tank. That’s nearly a 10 percent increase in the ranks of the uninsured, which alone will bring the uninsured rate close to 10 percent overall.

And many more will drop coverage in the years ahead, given ACA marketplace purchasers’ concerns about their ability to pay the new, higher rates without subsidies.

The $200 billion the Pentagon is requesting is sufficient to extend the ACA subsidies for over five years. Where did I get that estimate? The failure to extend the subsidies helped pay for the $7.7 trillion in tax cuts for the wealthy and large corporations in last year’s One Big Ugly Bill (OBUB). It reduced health care spending by about $350 billion over ten years, an average of $35 billion a year. $200 billion ÷ $35 billion = 5.7 years.

The same math applies to the alleged Medicaid “savings” in the OBUB. Imposing work requirements (a lexicographic subterfuge for erecting bureaucratic barriers that will make it difficult for qualified Medicaid beneficiaries to re-certify their eligibility) will cut an estimated $326 billion from the program over the next decade, according to the Congressional Budget Office. Cuts to the federal share of aid to state Medicaid programs will “save” the federal government another $300 to $400 billion. The two together add up to at least $65 billion a year ripped from Medicaid.

To sum up: Cuts in ACA subsidies and Medicaid in the OBUB will average over $100 billion a year over the next decade. At the rate the Trump regime is spending on the war against Iran, the Pentagon will eat that up in two years.

This accounting doesn’t take into consideration the long-term costs of U.S. involvement in overseas quagmires of its own making. The Iraq War, which began in 2002, cost close to $1 trillion in direct military spending. The long-term cost of caring for the wounded, veterans’ special health care needs, and related spending has been estimated to cost an additional $2 to $3 trillion.

Those of us old enough to remember the Vietnam War will recall the “guns and butter” debate that accompanied President Lyndon B. Johnson’s slow descent into that quagmire. LBJ’s advisers assured him the U.S. could do both.

Wrong. Inflation began escalating by the late 1960s, throwing the country into a recession by December 1969. During the decade after regular combat began in 1965, prices rose by a total of 176 percent, twice the rate of inflation during the previous decade. The biggest increases were triggered by soaring oil prices due to an Arab oil embargo after the 1973 Middle East war.

President George W. Bush tried his hand at guns and butter in 2003 when, to bolster his reelection chances amid widening opposition to the Iraq War, he pushed through an unfunded Medicare drug benefit and pushed further deregulation of the financial sector. By the end of his term in office, the resulting housing bubble and sub-prime lending crisis led to the worst economic downturn since the Great Depression.

While looking up some of the specifics of that history, I stumbled across the origination of the phrase “guns and butter.” It wasn’t a 1960s coinage. It was popularized during the 1930s by German Reich Marshall Hermann Goering, who defended Germany’s huge military build-up by saying, "Guns will make us powerful. Butter will only make us fat."

It was Theodor Reik, a Jewish intellectual who fled Nazi Germany, who in 1965 took issue with the idea that history repeats itself. “This is perhaps not quite correct,” he said. “It merely rhymes.”

What does the Trump regime’s escalating military spending amid evisceration of social spending rhyme with?

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News


Judge Rejects RFK Jr's Unfit Vaccine Committee In Sweeping Decision

Judge Rejects RFK Jr's Unfit Vaccine Committee In Sweeping Decision

So much damage has already been done.

Measles outbreaks are raging in four Red states. The Center for Disease Control and Prevention has dramatically scaled back its vaccine recommendations. Vaccination rates among young children are plummeting, especially in the South and rural West. Manufacturers are backing away from developing new vaccines.

In recent months, the Trump administration’s CDC, under the thumb of Health and Human Services Secretary Robert F. Kennedy Jr., has stopped recommending six routine childhood vaccines, including the flu, hepatitis A, rotavirus and meningococcal shots.

It will take years to undo the damage this already has done and will continue to do to public health until those policies are reversed. Here’s hoping this week marks the beginning of a turnaround.

Yesterday Massachusetts federal judge Judge Brian E. Murphy forbade the CDC’s newly-appointed Advisory Committee on Immunization Practices from taking further action to dismember U.S. vaccine policy. He ruled Kennedy violated federal law last June when he summarily fired the standing 17-member Advisory Committee on Immunization Practices (ACIP) and appointed eight replacement members, most of whom are avowed vaccine skeptics or critics of the Biden administration’s Covid policies. Another two appointed in January are similarly biased.

That’s not how Kennedy described his action nine months ago. He called the standing committee “a rubber stamp for industry profit-taking agendas.” He promised his hand-picked replacement committee would follow “unbiased science—evaluated through a transparent process and insulated from conflicts of interest.”

Kennedy violated both of those legal requirements, the judge ruled in a suit filed last year by the American Academy of Pediatrics and the American Public Health Association. “There is a method to how these decisions historically have been made—a method scientific in nature and codified into law through procedural requirements,” the 45-page order said. “Unfortunately, the Government has disregarded those methods and thereby undermined the integrity of its actions.”

He continued: “The Government bypassed ACIP to change the immunization schedules, which is both a technical, procedural failure itself and a strong indication of something more fundamentally problematic: an abandonment of the technical knowledge and expertise embodied by that committee.”


A Law Nixon Signed

The Federal Advisory Committee Act, signed into law in October 1972, requires agencies vet potential members of outside advisory committees for bias and conflicts of interest. It also requires the public be allowed to review and comment on the nominees. If an agency chooses someone with a conflict of interest, which can include a demonstrated intellectual bias, it must issue a waiver that documents why that particular person’s expertise is necessary before allowing them to serve.

(Full disclosure: I spent 2004 to 2009 at the Center for Science in the Public Interest monitoring science-based federal advisory committees’ compliance with FACA. I also served on Food and Drug Administration advisory committees. I am familiar with the law.)

Kennedy did none of that, drawing a black curtain around his promised “transparent process.” There was no public input before Kennedy made his choices. And there is no evidence (the FACA database, operated by the General Services Administration, has been non-operational for months) that any received waivers despite clear evidence that many had preconceived notions about the direction the committee should take.

Lawyers for the plaintiffs hailed the judge’s ruling. “This is a tremendous victory for science, for public health, and for the rule of law,” Richard Hughes IV, a partner at Epstein Becker & Green, told Stat News. A spokesperson for HHS said the agency would appeal.

Not 'A Reckless Ideologue'

The vice chairman of the new ACIP committee is Robert W. Malone, a physician and adjunct professor at Louisiana State University who has posted numerous articles on his Substack expressing doubts about current vaccine policy. He claimed in his post yesterday that “Kennedy’s reforms are not the work of a reckless ideologue (but) represent a serious effort to apply rigorous scrutiny to vaccine recommendations that have gone largely unquestioned for decades.”

Rigorous scrutiny? The evidence presented at the early December meeting of the reconstituted ACIP compared the U.S. to Denmark, a small, homogeneous country with far fewer health problems. It elevated patient and parental “choice” to a core principle of vaccine policy, not adherence to medical science.

The committee recommended the CDC scale back its vaccine recommendations. The administration formalized that action in a long memo a month later when acting CDC head Jim O’Neill unilaterally reduced the number of recommended childhood vaccines from 17 to 11. That step was taken “without public comment, and without initial review of the evidence by designated advisory bodies,” according to former public health officials now at Manatt Health, a consulting firm. (The CDC only makes recommendations; states are free to set their own policies when it comes to public health.)

It’s likely Trump administration lawyers will find a friendly appeals court to lift the order. Any formal reversal in the destructive vaccine policy that is now official will have to await a change in administration, if and when it comes.

I’ll leave the last word to Families USA executive director Anthony Wright. “When politics override science, our children pay the price. Today’s decision helps ensure that medical evidence – not ideology – guides how we protect kids from preventable diseases. With this decision, patient and consumer advocates will continue to advocate for clear, evidence-based advice and access to key vaccines, fully covered without cost-sharing or other barriers…

“We commend the court for this ruling, but families should not have to depend on litigation to ensure their child can receive a routine vaccine. Evidence-based medicine keeps children alive and in school. Preventing disease should be the foundation of any healthcare system serious about confronting the next disease outbreak or finding the next cure.”

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

Vital 2026 Debate Over Health Care Shoved Aside By Trump's Illegal War

Vital 2026 Debate Over Health Care Shoved Aside By Trump's Illegal War

The polls have dealt Democrats a strong hand heading into the mid-term elections. Health care affordability has emerged as Americans’ number one pocketbook concern, with voters trusting the minority party far more than Donald Trump and the GOP on the issue.

But that reality is now shrouded by the fog of war. The looming quagmire in the Middle East – it’s already costing lives, treasure and depleting the nation’s arsenal – will dominate political discourse as long as the bombs continue to fall. The electorate will soon realize that this will be their new normal for many months, and possibly years, to come.

The political fallout is predictable. The quarter of the electorate that are MAGA diehards will rally round the flag. Another quarter in the antiwar left (myself included) will scream about the flagrant violations of international and domestic law while reminding Americans of the repeated fiascos in Vietnam/Afghanistan/Iraq. The minimally-engaged middle will split, vacillating between its pro-Israel, anti-Iran sympathies and the gnawing fear that any attempt at nation-building through force of arms – especially led by this Trump mob – is unlikely to end either soon or well.

From the perspective of domestic health care policy, there may some benefit to a pause in the discussion. Over the past several months, I’ve read a number of op-eds and articles offering reform plans from leading health care thinkers, each of whom has close ties to various factions within the Democratic Party. I was not impressed.

Big problems, especially when it comes to affordability, require bold solutions. They must directly address the health care spending crisis as it is being experienced by average Americans. Most importantly, it must address the affordability crisis as it is being experienced by the working age population — the 170 million people with employer-based coverage, where co-premiums are soaring, deductibles are rising, and co-pays for expensive treatments are out of control.

For any plan to win broad political support, it must provide immediate relief — minor fixes won’t get the job done. And, most importantly, proposed solutions must be easily understood by the general population so that politicians who champion them can win broad political support for the legislation.

It is especially disturbing to me that leading thinkers in and around the Democratic Party continue to assert competition policy will address the immediate affordability crisis. No reforms that rely on the magic of the market can succeed in health care because health care does not behave like other commodities. Every sub-sector of the health care economy – insurance, hospitals, physician services, drugs, medical devices – is marred by systematic marketplace failure.

Nobel Prize-winning economist Kenneth Arrow outlined this reality in a seminal article in the American Economic Review more than six decades ago. “The special economic problems of medical care can be explained by adaptations to uncertainty in the incidence of disease and in the efficacy of treatment,” he wrote. In plainer language: No one knows when they’re going to get sick and the outcomes from treatment are variable and cannot be determined in advance. In his article Arrow laid out the many “adaptations to uncertainty” that led to market failure in each health care sector before concluding: “The logic and limitations of ideal competitive behavior under uncertainty force us to recognize the incomplete description of reality supplied by the impersonal price system.”

Yet numerous health economists and policy pundits continue to push competition policy – rigorous enforcement of antitrust laws to bolster price competition – as the solution to the problem of the U.S. paying the highest prices in the world for drugs, hospital care, and physician services. The latest articulation of this point of view comes from Dr. Ashish Jha, the dean of the Brown University School of Public Health who served as President Biden’s Covid-19 coordinator in 2022 and 2023.

Competition will not save us

In the first three parts (Part 1, Part 2, Part 3) of what promises to be an eight-part series in the Boston Globe, Jha argues that Americans pay the highest prices in the world (true), not because they consume more health care (also true), but because “in many American communities, there have been real breakdowns in the market. Patients largely cannot shop because they have too few choices (and) prices are opaque”

His solution is to break up the monopolistic hospital and insurance chains that dominate most regional health care markets in the U.S. In his most recent piece, co-written with Dr. Thomas Tsai, who teaches surgery at Harvard Medical School, they address the hospital sector, which is close to 40 percent of all health care spending. Jha and Tsai would foster competition by repealing certificate of need laws (a holdover from 1970s-style regulation that requires government approval of new facilities); allowing physicians to own hospitals; and encouraging more growth of ambulatory surgical centers, the in-and-out shops for minor procedures. This added competition, they conclude, will bring prices down and thereby lower household and business insurance premiums.

This approach represents the triumph of economic theory over experience. Most health care services are not even knowable in advance, much less shoppable. No one in the middle of a heart attack goes looking for the lowest cost ER. Chronic disease treatments (for cancer, diabetes and heart failure, for instance, which account for the majority of health care expenditures) are driven by physician prescriptions and recommendations, not consumer choice.

While estimates vary, shoppable services (low-cost lab and imaging tests; or discretionary cataract and replacement joints surgeries, for instance) account for less than 20 percent of all health care spending. Lowering costs for this limited set of services does nothing to relieve the financial pain of families in insurance plans with high deductibles and co-pays, who are forced to pick up thousands of dollars each year for the ongoing treatment of their chronic conditions.

Moreover, opening the floodgates to more supply is no guarantee that it will lead to lower spending. Jha and Tsai failed to consider what is commonly known as Roemer’s law, named after a Cornell University professor who in the early 1960s pointed out that hospital beds that get built tend to get filled. Studies over many years (most famously through the work at Dartmouth University by Dr. Jack Wennberg and colleagues, who relied on Medicare data) have found that physician and hospital practice patterns are wildly variable across the country, with local supply rising to meet whatever demand that local practitioners generate. This has also been proven true in the broader private insurance market.

Do we really want physician-owners of an gastroenterology ASC encouraging more seniors over 75 to undergo routine colonoscopies? Or more cardiologists recommending under-65 individuals with stable angina to undergo PCI interventions at the catheterization labs they own? A host of new physician-owned hospitals and ASCs could easily lead to more demand and spending, not less.

Even if more competition were to have the desired effect of lowering prices and total spending, it would take years before health care consumers saw any benefit through reduced premiums and co-pays. Busting up monopolies can take up to a decade in the courts. Constructing new facilities can take years. As a political program, it offers no immediate relief to householders struggling now with unaffordable health care bills.

The incrementalist trap

While the Jha/Tsai free market approach may appeal to the corporate wing of the Democratic Party, progressive health care economists, think tanks and patient/consumer advocacy groups continue to pursue incremental approaches to reaching universal coverage, improving benefits and lowering individual and families’ out-of-pocket spending. Their immediate struggle, which polls shows is backed by a clear majority of the electorate, involves fighting to reverse the massive setbacks suffered during the first year of Trump’s second term as president.

The damage will take its biggest toll starting next year unless Democrats win a veto-proof control of both houses of Congress, an unlikely scenario. Their demands are simple: First, restore the enhanced subsidies for Affordable Care Act plans whose expiration has massively increased health insurance costs for the millions of Americans who rely on purchasing individual and family plans on the exchanges. Second, restore the trillion dollars cut from Medicaid and eliminate the bureaucratic roadblocks to meeting the new work requirements and twice-yearly reassessments that will lead to millions of low-income people dropping the coverage they deserve. These advocates and the Democratic party are also fighting at the state level to raise taxes to offset the cuts, assuming, even if there is a blue wave, they won’t win a veto-proof majority.

Yet none of these efforts will have much impact on the half the population who depend on employer-based health insurance, where total costs and employee co-premiums, deductibles and co-pays are soaring. Those 170 million people are seven times more than the 24 million people with exchange-based plans, and 2 ½ times the number of people on Medicaid, all of whom are poor and less affected by rising costs.

This failure to grapple with the cost problem in the private insurance market was evident in a long interview Nobel Prize-winning economist Paul Krugman conducted last month with Jonathan Gruber, the Massachusetts Institute of Technology professor who was one of the main architects of the Affordable Care Act in 2010. They spent nearly half the hour-long interview lamenting the Trump/GOP cuts; condemning under-insurance due to the increasing number of people in high-deductible plans; and the negative health consequences of the escalating level of financial toxicity in the system. Finally, Krugman got around to asking the key question:

“What next? Do you think we can actually move forward and get the system better, besides just restoring the subsidies?”

Replied Gruber: “I think it’s going to be modest changes. I mean, essentially, even if we restore the subsidies, we’ll have 30 million uninsured Americans. Who are they? 10 million are undocumented immigrants. There’s zero political consensus for writing them insurance. About 10 million are people who simply think they’re too healthy to pay for insurance, and without a mandate we’re not going to get them.”

He went on to describe what he suggested will become the next big issue in health care: Providing adequate long-term care and home health for a rapidly aging Baby Boom generation. That will require more immigration, not less, he said, since there aren’t enough native Americans willing to take jobs in these very low-paying but fast-growing fields. “We estimate that you could provide a universal home care program that’s very reasonable for about $40 billion a year, which is really chump change compared to the (Trump) tax cuts,” Gruber said.

Only near the very end of the interview did Gruber switch his focus to the fact Americans pay the highest prices in the world, which is the root cause of the affordability crisis. “The market fails nowhere worse than in health care,” he said, citing Arrow’s paper. “Every other country in the world has recognized that, and they regulate the prices paid in health care. We haven’t. So I think that’s going to be the next big debate,” he said.

But how?

The left-of-center reformers

Dr. Ezekiel Emanuel, a bioethicist/oncologist at the University of Pennslvania and a senior fellow at the Center for American Progress, has the ear of policymakers in the Democratic Party. He recently offered a plan in an op-ed in the Washington Post that would put limits on health care prices in the private sector.

Full disclosure: In 2022, I worked with Emanuel and two others on two Health Affairs articles that explored Maryland’s single-pricing/global budgeting system. We concluded with a recommendation that states adopt the Maryland model, which CMS confirmed in 2021 had saved the federal government more money that all the other alternative payment programs initiated by the agency.

Maryland requires every hospital charge every payer (whether covered by Medicare, Medicaid or private insurance) the same price for the same service, and sets those prices at levels designed to keep spending within a global budget whose growth is limited from year to year. Adopting the Maryland system would lead to higher prices for government payers, who currently pay the lowest prices; and lower prices for private payers, who currently pay the highest prices. It also trims hospitals’ and insurers’ bloated administrative costs since it eliminates the need to negotiate and maintain multiple pricing schedules.

These measures would provide immediate relief to businesses and their employees in the form of reduced premiums and co-premiums. If global budgets were set below the rate of economic growth, the rate of spending growth would slow gradually, giving providers time to adjust while guaranteeing future premium increases would be at or near the overall inflation rate, not two or three times higher as they are now. In the decade since global budgeting was added to to Maryland’s single-pricing system, the state has had one of the slowest growth rates in health care spending in the country.

Unfortunately, Emanuel shied away from comprehensive payment reform in his latest proposal. Instead, he offered a five-point program whose first priority was setting price limits for private health insurance payments at a fixed percentage of Medicare prices. Currently, private prices are about 254 percent of Medicare prices, according to a 2024 survey conducted by the Rand Corporation. “This would reward competition among hospitals and lower bills,” he wrote.

I foresee several roadblocks to adopting a cap on private pricing. First, it will engender massive opposition from hospitals and physician practices, which would see an immediate sharp reduction in total revenue from their best-paying customers. It would not reduce administrative costs since different insurers would still negotiate and maintain different rates under the cap, depending on the number of covered lives they brought to the table. And while capped private prices would immediately lower total premium costs for employers, there’s no guarantee they would share those savings with their employees.

The other four points in the Emanuel program are of interest to policy wonks, but would have little immediate effect on the affordability of current private insurance plans. His proposals include: Paying doctors through bundled payments, not multiple billing codes; equalizing hospital in-patient and out-patient rates, so-called site-neutral payments; increasing spending on primary care; eliminating excess payments to Medicare Advantage plans; forcing insurers to offer the same prices to self-insured employers, whose plans they administer, as they offer to those they fully insure; reforming the pharmacy benefit manager system (already underway in Washington); requiring more rapid adoption of biosimilars; and cutting administrative costs through automating scheduling, quality reporting, data entry and customer service functions.

This is the type of multi-point program that policy wonks love, few people will read and even fewer will understand. It can’t be reduced to a slogan or be summarized in a 240-word social media post that convinces people they will benefit from these incremental and highly technical changes.

Moreover, the program’s only stab at providing immediate relief is setting a cap on deductibles (the amount people must pay in any given year before insurance kicks in) at two percent of the median household income, or about $1,650. While that sounds good, it will be of little solace to the 59 percent of U.S. adults who reported in a survey last year that they couldn’t afford a $1,000 surprise bill. It’s also unfair. A flat cap pegged to the median income provides its greatest benefits to those who earn more and can easily afford the new cap, while it takes a higher share of income from those who earn less. What’s needed is a percentage cap on all out-of-pocket expenses that is pegged to household income. In other words, the cap should be based on each individual household’s ability to pay.

The single-payer abdication

I would be remiss if I didn’t take into account the one-third to two-thirds of the electorate that currently backs single-payer health care, frequently called Medicare for All, as the ultimate solution to the affordability crisis. That wide variation in recent public opinion polls depends on how the question was posed in the surveys.

The Pew Research Center survey of 10,357 adults conducted last November found just 35 percent of favored “a single national health insurance system run by the government.” That same month, Data for Progress, which is affiliated with the Democratic Party-oriented Center for American Progress, asked 1,207 “likely voters” whether they backed “creating a national health insurance program, sometimes called ‘Medicare for All,’ that would cover all Americans and replace most private health insurance plans.” Sixty-five percent offered either “strong support” (36 percent) or “somewhat support” (29 percent).

When the D4P pollsters followed up by asking whether they would still back M4A if it “eliminate(d) most private insurance plans and replace(d) premiums with higher taxes, while guaranteeing health coverage for everyone and eliminating most out-of-pocket costs like co-pays and deductibles,” support fell to 63 percent with those strongly backing M4A falling six percentage points to 30 percent while “somewhat support” rose to 33 percent.

Many Americans, it would seem, so distrust the government that they wish it would keep its “hands off my Medicare” (as the much-lampooned sign at a 2009 South Carolina Town Hall read). Moreover, they begin to back away from supporting M4A as soon as they learn it will lead to higher taxes.

Medicare and Social Security remain the nation’s two most popular social insurance programs, still invulnerable to political attack, and still run by the government. Vermont’s Socialist Senator Bernie Sanders, through his two runs for the Democratic Party presidential nomination, made M4A one of his keystone planks and deserves credit for building a popular base of support for the program, which now commands the votes of over half the party caucus in the House.

But those Democrats have never developed the tax reform program that would be necessary to implement M4A, at least not one that is capable of unifying the party and winning majority support in Congress. American businesses through private insurance paid for 18 percent of all health care expenditures in 2024, according to the actuaries at CMS. Householders, through co-premiums, deductibles, co-pays, direct payments, Medicare Part B premiums and Medicare payroll taxes, pay for a whopping 28 percent. Relieving businesses of their direct payments and individuals of “most out-of-pocket costs” would require raising somewhere between $1.5 and $2 trillion a year in new revenue. That’s three to four times the amount collected in corporate income taxes in 2024; it’s 75 to 80 percent of individual income tax collections.

Those amounts could be sharply reduced if the legislation enacting M4A left Medicare payments rates where they are today, which average about 40 percent of private insurance rates. But that would entail hospitals, physicians, nursing homes and other providers taking a huge pay cut because patients who were previously insured privately would now be paying Medicare rates. For that reason alone, organized medicine and the hospital associations, whose memberships are located in every state and community in the nation, remain vehemently opposed to M4A, as they have been since it was first proposed by President Harry Truman in 1948. The insurance industry, needless to say, is existentially threatened by M4A, thus presenting a united front of corporate opposition within the health care sector. Their combined political clout has succeeded in keeping M4A off the national agenda, and will for the foreseeable future.

In the past year, M4A advocates have begun focusing on a more limited agenda: rescuing Medicaid, which is now under full scale assault by the Trump administration and the GOP-run Congress. Adam Gaffney, an associate professor at Harvard Medical School and past president of Physicians for a National Health Plan, last month offered an enlightened history of the program’s adoption and evolution in an article in the New York Review of Books.

After reviewing the devastating impact that the $1 trillion in Medicaid cuts will have on beneficiaries (his own research projects 16,000 people will suffer preventable deaths and 1.2 million people will accrue additional medical debt), he turned his attention to the work requirements newly imposed on the program – an extension of the “Elizabethan poor laws tradition of separating the ‘deserving’ from ‘undeserving’ poor.”

It’s been that way since its very beginnings in 1965, when it was tacked onto the legislation creating Medicare. The southern Democrats who controlled key committees in the House, backed by the American Medical Association and other health care lobbying groups, worried Medicare would be an opening wedge for adopting a national single-payer system, with poor people without employer-based coverage being the next group added to the rolls. So they created a separate program that states, “particularly Southern states, could control,” he wrote. “Rightly or wrongly, it was seen as less of a threat to the established, segregated medical order, which treated some people as second-class citizens.”

Over six decades, the 50 state programs have evolved in ways that reflect local choices, with all the biases that entails. Some states are generous, others are punitive; some cover most able-bodied adults, some very few or none at all; 10 states, including most of the deep South, have yet to expand Medicaid under the Affordable Care Act, despite the federal government offering to pay for 90 percent of the cost. Moreover, “Medicaid has also long generally reimbursed providers at a lower rate relative to other insurers, contributing to so-called informal segregation in healthcare provision,” he writes. “Such segregation takes place both across institutions and within them.”

Near the end of his well-written piece, he lays out the political argument for moving to a universal system by quoting Wilbur Cohen, the New Deal-era bureaucrat who stayed in government long enough to shepherd Medicare and Medicaid into existence. “Even as a committed incrementalist, Wilbur Cohen never lost sight of the benefits of universal systems,” he wrote. In a 1972 debate with conservative economist Milton Friedman, Cohen argued the universal case by stating “A program that deals only with the poor will end up being a poor program” since it will lack sufficient public support. For that reason, Cohen argued, “one must try to find a way to link the interests of all classes in these programs.”

Gaffney, like most M4A advocates, is not an incrementalist. He did not call for merging 50 state Medicaid programs into Medicare – something that should have been done in 1965 and still could be done today. Such a merger would generate huge benefits for its clientele in terms of increased access and more comprehensive benefits; it would lead to better pay for safety net providers; and it would provide massive tax relief for the states, who could then devote more resources to education, transportation and public safety — programs that, unlike health care, are best left to local control. The federal taxation required for a Medicaid takeover would be a third of what it would cost to nationalize the entire system. I made the case for federalizing Medicaid in this 2017 article in Democracy: A Journal of Ideas.

As I’ve attempted to show in this review, leading thinkers in and around the Democratic Party are mostly focused on undoing the damage done by the GOP and Trump over the past 14 months. Their proposals for incremental reforms are limited in scope and are unlikely to generate popular enthusiasm in the broader population. They have yet to come up with a comprehensive, achievable program that addresses the immediate affordability issue that is plaguing the majority of Americans, who are in employer-based plans and find themselves absorbing unsustainable increases in their co-premiums, deductibles and co-pays.

In my next post, I plan to revisit my bold proposal to make health care affordable for all, and show why this incrementalist approach is both achievable politically and necessary for putting the U.S. on a path toward a more affordable, higher quality and sustainable health care future.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News

Stressed Out? You've Endured A Year Of Spiraling American Health

Stressed Out? You've Endured A Year Of Spiraling American Health

Two snapshots of a health care system in precipitous decline: First, the latest Kaiser Family Foundation tracking poll shows Americans’ number one pocketbook concern is now the cost of health insurance and out-of-pocket health care expenses. Fully two-thirds of the public are more worried today about health care costs than food, housing, utilities or gasoline.

Second, the Centers for Medicare and Medicaid Services reports that 1.2 million households dropped health insurance coverage during the 2026 sign-up season, a direct result of the Republican Congress ending the enhanced premium subsidies for Obamacare plan purchasers. The missing 1.2 million came from just 30 states that use the federal exchange.

When the other 20 states report (many have extended the sign-up season to the end of this month), that number will likely reach the 2.2 million that the Congressional Budget Office predicted would drop coverage. The KFF poll found 67 percent of voters now oppose ending the expanded subsidies, including 89 percent of Democrats and 72 percent of independents. Democratic Party attempts to restore the subsidies led to a 43-day government shutdown in October and November.

Those two news items prompted me, in this last post before a three-week break, to take a brief look at where the overall health of the nation and health care policy stand a little over one year into the second Trump administration. I begin by resuscitating a question raised by another Republican president nearly 46 years ago: Are we better off today than we were a year ago?

As sports announcers like to say, let’s go to the video tape.

Compared to one year ago, we have:

  • Falling health insurance coverage and a rising uninsured rate.
  • Declining health care affordability.
  • Less vaccine access.
  • Large measles outbreaks.
  • States eliminating water fluoridation.
  • Less money for public health departments.
  • Less money for Medicaid.
  • Less money for NIH research, and ideological controls placed over its content.
  • Less money for substance abuse treatment.
  • Less money for HIV prevention.
  • Less money for global health.

Among the social and economic determinants of health (which have a greater impact on the general population than health care system interventions), we face:

  • Rising unemployment.
  • Rising inflation (especially for health care and groceries).
  • Fewer food stamps.
  • Less affordable housing.
  • Declining consumer confidence.

Less in the pipeline, too

Every arena for improving public health last year suffered major cuts in federal support or detrimental policy reversals or both. Looking ahead, every public and private institution that must deal with the health consequences of a less generous social safety net faces the prospect of years of additional cuts in federal support due to the massive corporate and higher-earner tax breaks passed last year.

They will also have to deal with another “social determinant of health”: A level of social stress and political division that we’ve not seen since the Vietnam War. It is a direct result of the Trump regime’s violent and illegal assaults on America’s immigrant communities, conducted without regard for the citizenship, residency status or civil rights of those assaulted.

The toll so far: Nearly three dozen dead, including Renee Good and Alex Pretti through summary execution. Within immigrant communities, there now exists widespread fear, reduced school attendance, lost jobs and declining economic activity.

Mounting social stress extends well beyond those directly attacked by the poorly trained goons deployed by the Department of Homeland Insecurity. For a majority of Americans, there is growing recognition that we are on the cusp of losing our birthright as U.S. citizens — the right to the constitutional democracy that was founded 250 years ago and has long been a beacon to freedom-seeking peoples everywhere.

Instead, we’ve been forced to watch helplessly (and without effective push back by the minority party) as the executive branch daily flouts the rule of law; an obsequious, dysfunctional Congress that conducts no oversight; a politicized Supreme Court that enables flagrantly unconstitutional executive behavior; and an ongoing attack on free and fair elections by a Department of Justice that acts like the president’s personal law firm. All of this is either overlooked or temporized by a press run by oligarchs, who now control most of the mainstream media that reaches the broad mass of Americans.

The long-term health consequences of these dramatic changes in our daily lives cannot be predicted with certainty. But the one thing health researchers have repeatedly shown is that people under chronic stress are more prone to chronic disease. The Trump regime’s actions are, quite literally, ruining your health.

A Nation Under Extreme Stress

One need look no farther than public opinion polls to know that huge swaths of the U.S. population feels it is under tremendous stress. A Gallup Poll taken in mid-2025 showed over 18 percent of Americans report they have been either diagnosed or treated for depression in the past year, close to the highest level ever. The rate for young people under 30 is 27 percent — the highest ever.

Why wouldn’t young people feel depressed when the oligarch-controlled social media feeds streaming through their smart phones confirm daily that they are living live in a country on the brink of civil war; where an oppressed majority’s beliefs and values are daily being attacked by a regime that makes no attempt to govern on behalf of all the people; where those who express their anger and frustration through constitutionally protected speech and protest are branded as “domestic terrorists,” with their names, license plates and addresses recorded by masked government employees toting pistols and stun guns?

Should we be surprised that the Fall 2025 edition of the long-running Harvard Kennedy School Youth Poll found that nearly two-thirds of young adults (under 29) describe the U.S. today as “a democracy either in trouble (45 percent) or one that has already failed (19 percent).” Just four percent of Democrats and Independents would describe the U.S. as “a healthy democracy.” The number rises to only 12 percent among self-identified Republicans.

I wanted to end this review on a positive note, and the latest report on U.S. life expectancy from the National Center for Health Statistics, an arm of the CDC, provided the opportunity. It showed life expectancy rose seven months to 79.0 years in 2024, finally reaching and slightly surpassing its pre-COVID peak (although we’re still two to three years behind other advanced industrial countries). Analysts attributed the increase to reduced opioid overdose deaths and the waning effect of the pandemic.

A victory for Trump’s crackdown on the global fentanyl trade by blowing boats out of the water off in the Pacific Ocean and Gulf of Mexico? Hardly. The report covers 2024, the year before he resumed residency in the Oval Office. We’ll have to wait until next year to learn how much damage his actions and those of his minions have done to Americans’ health.

Merrill Goozner, the former editor of Modern Healthcare, writes about health care and politics at GoozNews.substack.com, where this column first appeared. Please consider subscribing to support his work.

Reprinted with permission from Gooz News